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1-1. Clinical Overview of Rheumatoid Arthritis 
The characteristic feature of rheumatoid arthritis (RA) is the development of joint 
damage and deformity due to chronic inflammation of the synovium, most notably swan-
neck deformities of the distal phalanges. Histologically this is manifested by a 
hyperproliferation of resident joint structural cells, which are intermixed with invading 
immune cells, forming a tissue termed the pannus. The RA pannus is thought to 
responsible for the cartilage and bone erosion leading to the eventual remodeling and 
disfigurement of the joint. However, RA is also a systemic inflammatory disease and can 
affect many organ systems outside the joint [1]. 
 
Despite RA’s profound impact on the body, it is a disease that defies absolute 
characterization, as there are no definitive features that are known to be entirely unique to 




classification of RA are typically used to diagnosis this disease [2]. These criteria are 
efficient in separating RA from other inflammatory arthritides and have a sensitivity and 
specificity of  90% [3]. Based on these criteria, the female to male ratio of RA is 
approximately 2 to 1, and it has a global prevalence of approximately 1% [4]. Beyond the 
biologic impacts of RA, it has been shown to have profound negative effects on quality of 
life as the disease progresses: The rate of disability by 10 years after the onset of disease 
is at least 50%, RA patients are hospitalized twice as frequently, and median life 
expectancy is reduced 7 years for men and 3 years for women [4]. 
 
1-2. T cell influences in RA 
Currently, the etiology of RA remains elusive. Several mechanisms have been proposed 
(T cell mediated, humoral/B cell mediated, cytokine networks, microbial pathogens), but 
no consistent factor documented in all cases of RA [5]. 
T cells in RA etiology 
Several lines of evidence suggest a T cell mechanism may be involved in RA 
pathogenesis [6]. Strong circumstantial evidence comes from the observation that the T 
cell is the most prominent infiltrating lymphocyte within the pannus. Enumeration of the 
invading lymphocyte population from digested synovial tissues showed that 
approximately 80% of the cells were T cells [7-9].  
 
Another observation supporting the role of the T cell in RA pathogenesis, comes from the 




that has been closely associated with RA incidence within the Caucasian population [10]. 
Several other MHC alleles, were also found to be associated with RA, and the “shared 
epitope” hypothesis of RA etiology was proposed based upon the amino acid residues 
from 70–74 of the DR β chain [11]. HLA-DR alleles associated with RA were found to 
possess QKRAA or QRRAA as a motif within this region. Possession of an allele 
containing the shared epitope also correlated with increased disease severity [12-14]. It 
has been hypothesized that the shared epitope can present a specific pattern of 
autoantigenic peptides distinct from other MHC II alleles [12].  Consequently, it has also 
been proposed that the T cell repertoire is shaped by education during thymic 
development against the shared epitope and that this skewed T cell population could 
contribute to RA pathology [15, 16]. It has even been suggested that the shared epitope 
itself could be presented by other MHC II alleles, thus creating a population of 
autoreactive T cells that would be activated by re-encountering the QKRAA motif within 
proteins of microbial pathogens [17, 18]. 
 
Unfortunately, no autoantigen has been consistently reported in RA nor has a pathogenic 
T cell clone been positively identified. Additionally, clinical trials testing T cell depletion 
by antibody directed at CD4 did not produce robust therapeutic effects [19, 20].  
 
However, recent trials have revived the concept of targeting the T cell as a therapeutic 
mechanism. The CD28 receptor on T cells receives co-stimulatory activation signals 
when bound by its ligand B7-1/CD80 [21-23]. To limit uncontrolled T cell activation, 




is an inhibitory receptor and has approximately 1000 fold greater affinity for B7-1 
relative to CD28, thus enabling it to out-compete activating signals [24]. By combining 
the human extracellular domain of CTLA-4 with the Fc portion of human IgG1, CTLA-
4Ig was created. In clinical trials, CTLA-4Ig (Abatacept) significantly improved RA 
patient outcomes as a monotherapy [25, 26], in combination with methotrexate [27], and 
in patients refractory to anti-TNF therapy [28]. These findings suggest that despite the 
negative results from T cell depletion trials, T cell modulation by inhibition of activation 
signals is a viable mechanism to treat RA, and that T cell activation contributes to RA 
clinical manifestations.  The rapidity of the onset of clinical benefit in controlled trials of 
CTLA-4-Ig indicates that T cells contribute actively to the inflammatory manifestations 
of this disease throughout its course, not just at disease initiation. 
 
With these considerations in mind, better characterization of the nature of T cell function 
in RA is an important research goal.  
T cell characterization in RA 
Two ways to better understand the T cells in RA is to characterize them by surface 
marker expression and by cytokine production. The CD4 marker characterizes the helper 
subset of T cells normally responsible for full adaptive activation of the immune system. 
The CD4 T cell subset in RA displays markers indicative of activation and in RA 
cytokines skew towards a Type 1 immune profile [29, 30]. Compared to CD4 T cells 
from peripheral blood, synovial CD4 T cells produced more IFNγ, a prototypic type I 
cytokine, and paradoxically IL-10, a normally inhibitory cytokine [31]. Characterization 




33]) on CD4 naïve and memory T cells, found that early activated CD4 T cells were 
found in perivascular aggregates of synovium and that the diffuse synovial T cells 
displayed the late activation loss of CD27 [34], suggesting a pattern of naïve CD4 T cells 
from peripheral blood progressing to late activation as cells migrate into the synovium, 
similar to what would be expected from T cells migrating from peripheral blood through 
a lymph node. 
 
Another peculiar characteristic of RA T lymphocytes, is the expansion of CD4+CD28null 
population in some patients. These cells display markers of autoreactivity [35], are not 
anergic [35], are resistant to apoptosis [36], and show signs of oligoclonality [37]. 
However the CD28 pathway has been shown to be intact in T cells hyporesponsive to 
CD3 activation [38] and CTLA-4Ig has been found to be therapeutic in clinical trials, 
reinforcing the concept that no one T cell population can easily account for all of the 
roles of T cells in human RA. 
 
Looking at another T cell subset, the CD8 T cells are primarily associated with cell-
mediated cytotoxic responses towards virally infected cells and malignancies. In RA, 
CD8 T cells have been shown to be crucial for maintenance of ectopic germinal centers 
in synovial pannus lesions [39]. Using human synovial tissue transplanted into SCID 
mice, it was demonstrated CD8 T cells were crucial for the maintenance of germinal 
centers and antibody production from human explants [40]. Not surprisingly the CD8 T 
cells expressed CD40L and were associated with lymphotoxin α/β production (a cytokine 





While the characterization of RA T cells continues, the exact type of pathologic T cell 
which could be responsible for disease initiation and maintenance is not adequately 
understood. 
1-3. B cell influence in RA 
Given the equivocal evidence for the primacy of T cells in pathogenesis and maintenance 
of RA, other cell types deserve evaluation. Though the B cell is not as numerous as the T 
cell in pannus lesions, it is found within those tissues. The initial suggestion that RA 
might be caused by a B cell abnormality was based on the observation of high levels of 
circulating autoantibodies in RA patients. Rheumatoid factors (RF) are autoantibodies of 
any isotype with specificity for the Fc portion of IgG. RF is generated during most 
immune responses, but RF persistence is associated with autoimmune disease [41]. RF 
has been shown to fix and activate complement and could potentially contribute to local 
inflammation [42, 43].  RF has not been shown to be a causative agent in arthritis when 
transferred into healthy individuals [44].  But, RF is a positive predictor of disease 
severity and progression in RA [45].  When combined with autoantibodies directed 
against cyclic citrullinated peptides (anti-CCP), RF and anti-CCP become highly specific 
for rheumatoid arthritis and negative clinical outcomes [3, 46-48]. Citrullinated proteins 
are proteins that have had lysine residues converted to citrulline residues by a deiminase 
reaction catalyzed by peptidylarginine deiminase [48]. 
 
Despite little evidence that autoantibodies are pathogenic in RA, B cell depletion trials 




[49, 50]. This suggests that in responsive patients, B cell antibody production might not 
be the only way that B cells contribute to RA pathogenesis, and that perhaps B cells may 
also participate in disease progress through antigen presentation, cytokine production, or 
cell-cell contact interactions. 
 
It should be noted that there are rare case reports of patients suffering from 
agammaglobulinaemia or hypogammaglobinaemia who meet the ACR criteria for RA 
[51, 52]. These patients lack mature B cells and circulating immunglobulins, yet still 
develop an inflammatory synovitis characterized by a T cell infiltrate as is seen in RA. 
1-4. Microbial infections – do they have a role in RA? 
Taking a step back, since a precise autoimmune, T cell or B cell mediated mechanism of 
RA etiology has been not proven, it is possibly that RA is a manifestation of an aberrant 
immune response to an invading or local pathogen. The evidence for microbial 
participation in RA pathogenesis is suggestive, but not conclusive. A variety of 
microorganisms or components of microorganisms can be detected in arthritic joints. It is 
suggested that perhaps, following an initial microbial infection in the joint or elsewhere 
in the body, immune responses might be directed into an aberrant reaction in the joint.  
Some viruses know to cause an inflammatory arthritis, and potentially affecting RA are 
parvovirus B19 [53, 54], Epstein-Barr virus (EBV) [55-57], and herpes simplex [58]. But 
there is also evidence against an RA association with viral infection as measured by viral 





Some bacterial pathogens implicated in RA are E. coli and mycoplasma.  Mycoplasma 
DNA has been detected in synovial fluid and tissue [61, 62]. Several clinical trials have 
documented positive clinical outcomes using antibiotics alone [63, 64] or in combination 
with methotrexate [65].  However, these reports do not confirm a mechanism of action 
for the antibiotics used, typically tetracyclines, which can also inhibit collagenases. 
 
E. coli heat-shock protein dnaJ contains the shared epitope sequence and synovial cells 
have been reported to respond to dnaJ [17]. Similarly EBV protein gp110 was also found 
to contain the shared epitope [66]. But again, the evidence for a microbial association 
with RA is inconsistent through all disease incidences. 
1-5. Cytokine networks in RA 
In contrast to the etiology of RA, the importance of the cytokine milieu in the joint has 
been better described clinically. Cytokine production in RA is robust and varied. 
Proinflammatory, immunoregulatory, chemotactic, and mitogenic cytokines have all been 
documented at the mRNA and/or protein level from RA tissues [67]. The pathogenicity 
of RA cytokine production was convincingly demonstrated by dramatic reduction in 
disease severity after cytokine neutralization in clinical trials. The first dramatic 
responses were seen with TNFα blockade with monoclonal antibodies [68, 69]. From 
these first trials new cytokine targets have emerged. Inhibition of IL-1 signaling 
pathways utilizing recombinant IL-1 receptor antagonist slowed radiographic progression 
of RA [70, 71]. Blockade of IL-6 by neutralizing antibody resulted in reduced clinical 
severity of RA symptoms [72, 73]. Unfortunately, cytokine neutralization is not curative 




underlying inflammatory process is still active despite the blockade of soluble 
inflammatory mediators. 
1.6 Fibroblast-like synoviocytes: active participants in joint destruction 
Normal synovial fibroblast function 
Looking the joint inflammation it is important not to solely focus on the invading 
lymphocytes, leukocytes, and pathogens. The resident cells native to the joint are also 
participants in the complex cell-cell interactions of the pannus. The normal synovium 
morphology is composed of an intimal layer 1-3 cells thick atop a subintima [74]. The 
intima does not contain a basement membrane, is exposed to the joint space, and is 
populated by two cell types [75]. They have been termed type A (synovial macrophage, 
macrophage-like synoviocyte, MLS) and type B (synovial fibroblast, fibroblast-like 
synoviocytes, FLS) synoviocytes. FLS help maintain joint homeostasis by synthesis of 
protein products that protect the joint space and control synovial fluid volume [75]. 
 
FLS are active participants in RA joint destruction 
Far from being passive structural cells responding to an inflammatory environment of 
cells and cytokines, the evidence indicates that FLS are active participants in joint 
destruction and maintenance of inflammation [75-77]. The most convincing evidence of 
the innate aggressive nature of RA FLS comes from transplant of human cartilage with 
pure populations of RA FLS into SCID mice [78]. RA FLS were observed invading 




cartilage degradation. Osteoarthritis (OA) FLS and dermal fibroblasts do not share this 
phenotype. 
 
FLS degradative enzymes 
FLS elaborate many degradative enzymes which can breakdown the extracellular matrix 
and connective tissue. Cultured FLS produce collagenase (MMP-1), stromelysin (MMP-
3), and MMP-10 de novo [79, 80], and secretion of these enzymes is correlated with 
invasive ability through artificial matrices. IL-1 and TNFα stimulation enhanced the 
production of stromelysin and collagenase from FLS, but did not enhance production of 
TIMP, implying conditions within the RA synovium favor production of factors leading 
to destruction of tissues versus tissue protection. Other pro-inflammatory factors are also 
present within the synovium apart from IL-1 and TNFα, including IL-6, TGFβ, and other 
mediators.  The multiplicity of factors which promote FLS destruction of cartilage is seen 
by retention of cartilage invasive properties after stimulation of FLS by synovial fluid 
incubated with neutralizing antibodies to the aforementioned cytokines [81]. FLS 
interaction with the extracellular matrix has also been shown to enhance MMP 
production [82]. A recent study using stable knockdown of MT1-MMP in FLS by 
retrovirus, has shown a reduced but not eliminated capacity of transfectants to invade 
cartilage in the SCID transplant model [83], suggesting that MT1-MMP is a major 





FLS hyperproliferation and apoptosis 
An attractive mechanism for synovial hyperplasia seen in RA would be simply the 
increased mitotic rate of FLS. FLS certainly proliferate when cultured ex vivo and 
cultures can be maintained for months [76]. The lining layer cells in RA synovium tissues 
also showed greater thymidine incorporation relative to OA tissues [84]. Within the RA 
joint there are also elevated levels of growth stimulating cytokines [75]. However, 
phenotypic characterization of the thymidine incorporating cells from synovial tissues 
revealed that thymidine was mostly incorporated by CD8 cells [85]. Similarly while 5% 
of cultured FLS showed positive DNA synthesis as an indicator of proliferation, only 1% 
of synovial lining cells in vivo displayed active DNA synthesis, suggesting mechanisms 
are present in the synovium to retard FLS growth [86]. 
 
An alternative method to explain increased FLS numbers in synovial lesions is defective 
apoptosis. The role of Fas (CD95) expression on RA FLS remains unclear. Initial studies 
indicated that stimulation by TNFα sensitized FLS to apoptosis through Fas ligation 
through the downregulation of FLIP [87, 88]. More recent studies reported results 
directly contradictory to the previous findings. These studies showed that FLIP levels are 
enhanced after FLS are stimulated by TNFα [89], and that FAS ligation on TNFα 
stimulated FLS lead to proinflammatory transcription factor activation, not apoptosis 
[89]. The studies indicating TNFα sensitization of FLS to apoptotic signals [87, 88], 
possibly could be due to FLS line variability in sensitivity to apoptosis [89]. Apoptotic 
resistance leading to increased inflammatory capability could explain increased FLS 





FLS cytokines and chemokines 
FLS release a plethora of soluble mediators involved in local inflammation, lymphocyte 
recruitment, angiogenesis, cellular activation and differentiation [75-77, 90-92]. The 
mediators released from FLS are indicative of their inflammatory state. Culture 
supernatants from FLS stimulate cellular replication in bioassays [93]. Comparing cDNA 
from RA FLS and OA FLS revealed a pattern of inflammatory cytokine production. A 
potent cytokine produced spontaneously by RA FLS is IL-15 [94, 95]. Synovial T cells 
migrate and proliferate in response to stimulation with IL-15 [96]. IL-15 enhances 
effector functions of T cells in the induction of TNFα by monocytes [97]. FLS also 
produce the osteoclast differentiation factor RANKL, and can induce osteoclast 
development from peripheral blood monocytes [98]. 
 
1.7 T cell-FLS interactions 
FLS activation by T cells 
Given the extensive infiltration of the synovial pannus by T cells, interactions between 
invading T cells and FLS could be important in RA pathogenesis. Based upon the heavy 
lymphocytic infiltration of synovial membranes, early experiments recapitulated T cell 
adherence to FLS via antigen independent mechanisms in vitro. Using unstimulated FLS, 
it was noted that activated T cells bound more vigorously to FLS than did resting T cells, 
and that this adhesive interaction could be partially inhibited by blocking the CD2/LFA-3 




TNFα, or IL-1β) the percentage of adherent T cells increased [100, 101]. These cytokines 
induced much greater expression of ICAM-1 (intercellular adhesion molecule-1, CD54) 
[101] and the adherent T cell subset displayed a higher expression of the ICAM-1 
counter-receptor LFA-1 (leukocyte functional antigen-1, CD11a/CD18) [100]. These 
studies note the decreased capacity of resting T cells to bind to FLS, which is probably 
due to the short time course of the adhesion assay.  
  
Expanding beyond adhesion assays, experiments on cocultures of T cells and FLS 
demonstrated that interaction between these cells types could activate FLS.  Phorbol 
myristate acetate (PMA) activated T cells triggered IL-1β transcription in FLS and 
release of IL-1 into culture supernatants, dependent on interactions between LFA-1 and 
ICAM-1[102].  LFA-1/ICAM-1 interactions are important in T cell adhesion and 
immunologic synapse formation between T cells and conventional antigen-presenting 
cells (APC).  It was noted that resting T cells did not adhere within a time course of 30 
minutes, while PMA-treated T cells had firm LFA-1/ICAM-1 mediated adhesion.  
Potential limitations of this study involve its use of SV-40 transformed FLS lines and 
PMA treatment of T cells.  The transformed FLS constitutively expressed ICAM-1 at a 
high level that was uninfluenced by IL-1β, suggesting a preactivated state, while PMA 
activation of T cells might not be physiologically relevant.  Nonetheless, this study 
demonstrates the potential for antigen-independent interaction of T cells with FLS, 
leading to inflammatory mediator production. More physiologic activated T cells have 
also been show to activate FLS. Comparing IL-2 expanded T cells from both RA 




both T cell types produced factors that enhanced FLS growth, but that clones derived 
from synovial fluid produced more [103]. The growth effect of these factors was not 
attributed to IFNγ or IL-2. 
 
Work in our laboratory has also focused on the interaction between T cells and FLS. It 
was found that even resting T cells could stimulate FLS. Using resting T cells as a 
stimulus, we have documented activation of FLS and release of proinflammatory 
mediators [104].  We found that autologous or allogeneic resting T cells have similar 
activating potential on FLS.  This effector function of resting T cells is not restricted to a 
particular T cell population.  Various subsets of T cells, CD4+, CD8+, CD45RO+, and 
CD45RA+ all had comparable ability to induce synovial fibroblast activation.  Activated 
FLS showed induction or augmentation of mRNA for stromelysin, IL-6, and IL-8, gene 
products important in joint inflammation and joint destruction.  Furthermore, increased 
production of IL-6 and IL-8 was quantitated both by ELISA and by intracellular cytokine 
staining.  Another striking observation was that the T cell specific cytokine IL-17 
synergized with T cells to active FLS.  These coculture systems spanned up to 24 hours 
and no T cell activation was noted, by assessing upregulation of CD154/CD40L or CD69.  
Thus, using resting T cells as a stimulus on untransformed FLS lines, we documented 
further evidence of T cell-FLS antigen independent interactions resulting in induction of 
an inflammatory profile of FLS. 
   
Two studies have recently provided further support for a role of T cell activation of FLS 




the other used collagen type II (CII) responsive T cells [106].  Both studies cite the 
importance of IL-15 expression by FLS and its upregulation after stimulation by T cells 
[105, 106].  The first study utilized unstimulated T cells purified from peripheral blood or 
RA synovial fluid.  After 96 hours of coculture with these T cells, induction of ICAM-1, 
IL-8, IL-6, and IL-15 was noted on the FLS [105].  This induction was dependent on cell-
cell contact, as evident when transwell inserts separating T cells from FLS blocked 
activation.  Similarly blockade of CD69, CD11a, IL-17, TNFα, and IFNγ also inhibited 
activation of FLS.  Another interesting observation was that T cells showed signs of 
activation by induction of CD69, CD25, IL-17, TNFα and IFNγ after coculture with FLS 
[105].  This is contrary to our findings described above [104], and the discrepancy is 
explained by the duration of coculture, 96 versus 24 hours.  T cell responses were blunted 
by blocking antibodies towards ICAM-1 and IL-15, demonstrating the importance of FLS 
factors for T cell stimulation.  When CII activated T cells were used as the stimulus, FLS 
displayed production of TNFα, IL-15, and IL18 [106].  These CII activated T cells were 
generated by culture of T cells with bovine CII and autologous irradiated APC for 
extended periods.  An intriguing observation was that the increased length of stimulation 
of CII before coculture with FLS resulted in increased IL-17 and IFNγ production by T 
cells, which implies the level of T cell activation is proportional to the effector function. 
 
Cross-talk between T cells and FLS 
FLS are not the only “beneficiaries” in cocultures with T cells. IL-2 expanded T cells 
rapidly die after withdrawal of cytokine stimulation. FLS were able to rescue IL-2 




FLS cytokine production and was thought to be mediated by an unknown stromal factor. 
RA synovial T cells display a phenotype indicative of susceptibility to apoptosis: low 
Bcl-2, high Bax, and high Fas [108].  However, these T cells are resistant to apoptosis 
relative to T cells from crystal arthritis, but die when removed from the joint. Rescue of 
both RA synovial T cells and gout T cells occurred when they were cultured with FLS. 
Integrin interactions are implicated in the survival signals, as RGD peptide stimulation 
enhanced T cell longevity [108]. 
 
Long term cultures of RA FLS with autologous T cells results not only in long term T 
cell survival, but also T cell expansion [109]. This mechanism behind this observation 
was attributed to TSP1 on FLS stimulating CD47 on T cells in a costimulatory fashion 
distinct from CD28 [109].  However, a role for other receptor-ligand interactions is not 
excluded. 
 
As previously stated, T cell coculture with FLS results in the upregulation of the 
activation markers CD69 [105, 110] and CD25 [105], and this process is dependent on 
FLS IL-15 and ICAM-1. 
 
FLS as APC 
The above observations describing FLS and T cell cross signaling were conducted using 
antigen free systems. Studies have also explored the role of FLS as APC for T cells. 
Initial experiments using human dermal fibroblasts showed that fibroblasts were poor 




expression of MHC II, but was due to lack of an accessory molecule that could be 
provided by conventional APC.  However, it was noted that dermal fibroblasts could 
stimulate previously activated allogeneic T cells [111].  Expanding on this work, the 
capacity of dermal fibroblasts to function in antigen presentation was evaluated.  Dermal 
fibroblasts were able to process antigen, but did not function well as APC without 
accessory cell help [112].  In both these studies INFγ was used to induce MHC II, and 
antigens relevant to RA were not evaluated.  These studies do document fibroblast 
expression of functional MHC II.  Another report documents costimulatory properties of 
FLS dependent on IFNγ or IL-1 stimulation [113]. 
 
FLS of RA synovium express high levels of MHC II ex vivo [114], indicating the 
potential for antigen presentation by FLS in RA.  Early studies suggest that FLS can 
process antigen similarly to professional APC [115].  In those experiments, FLS were 
able to take up and process various antigens, and present them to T cell clones via an 
MHC II restricted mechanism [115].  This gives support to potential antigen specific 
interaction between T cells and FLS (as APC).  However, antigens relevant to RA were 
not assayed nor were observed responses robust. 
 
Our laboratory also observed MHC II dependent signaling between FLS and T cells.  
Superantigens activate FLS to secrete inflammatory mediators and potentially participate 
in RA pathology.  Thus, we assessed the ability of IFNγ treated FLS to present 
superantigens to T cells [116].  FLS can indeed present superantigens, inducing resting T 




LFA-1, and the cytokine IL-2.  This study provides a mechanism for FLS to activate 
naïve T cells, but does not demonstrate an “antigen specific” response to autoantigens or 
to peptide antigens that are presented in the cleft of the MHC molecule. 
 
There is also evidence that FLS might not activate T cells, but instead induce anergy 
[110].  These experiments assessed the APC and allostimulatory functions of FLS.  
Similar to previous studies, FLS were able to load antigen onto MHC II.  However, 
allogeneic responses depended upon the addition of accessory cells expressing CD80, and 
blockade of CD80 abolished the response.  When FLS without accessory cells were 
cultured with T cells, they adopted a phenotype resembling anergy:  upregulation of 
CD25, reduced proliferation, and reconstitution of proliferation by exogenous IL-2 (21).  
Similar to other studies, CD69 on T cells was also upregulated after T cell culture with 
FLS.  This study implies that FLS cause anergy due to a lack of costimulatory molecules, 
but that bystander cells expressing costimulatory molecules could overcome this.  The 
potential for accessory costimulation exists abundantly within RA synovium due to the 
close proximity of FLS with B cells, macrophages, and dendritic cells. 
 
1-8. Thesis objective 
Given the unknown etiology of RA, the data supporting active FLS participation in 
pathology, and the unusual interactions between T cell and FLS, this thesis sought to 
explore the mechanisms involved in T cell-FLS bidirectional signaling as a pathologic 
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2. Antigen Presenting Cell Function of FLS for Autoantigens 
 
2-1. Summary 
The abundance of both T lymphocytes and fibroblast-like synoviocytes (FLS) in 
rheumatoid arthritis (RA) synovium suggests that interactions between these two cell 
types could be important in the pathogenesis of RA. FLS express high levels of MHC II 
in vivo, suggesting that these cells might present peptide antigens to T cells. We found 
that human FLS could present peptides from the autoantigens human cartilage gp39 
(HCgp39) and human collagen II (hCII) to antigen-specific MHC-restricted T cell 
hybridomas derived from a human HLA-DR4 transgenic mouse. This response required 
pretreatment of FLS with IFNγ, showed MHC restriction, and was dependent on human 
MHC II and murine CD4 for effective antigen presentation. Furthermore, FLS were able 
to extract and present antigens found within human synovial fluid to both the HCgp39 




context of inflamed synovial tissues, FLS may be an important and hitherto overlooked 
subset of APCs that contribute to joint pathology. 
2-2. Introduction 
In contrast to the usual functions of fibroblasts, FLS have been hypothesized to be 
important in joint inflammation and destruction [1-4]. In RA, FLS adopt an inflammatory 
phenotype, and secrete cytokines, proteases and other mediators. FLS secrete chemokines 
that enhance leukocyte recruitment through synovial endothelium [5]. The most abundant 
infiltrating leukocyte is the T lymphocyte, which may come into close proximity to FLS, 
and interaction between these cells could contribute to RA pathology. When FLS and T 
cells are co-cultured in vitro, activation of both cell types is observed. FLS produce 
inflammatory mediators such as IL-6, IL-8, and prostaglandin E2 [6], and T cells 
upregulate the activation markers CD69 and CD25 [7]. The functional consequences of 
these co-cultures mirror the molecular characteristics of RA synovium, which suggests 
that similar interactions could be occurring within the inflamed RA joint. These 
experiments were performed without addition of antigen; thus, the bidirectional 
activation observed was by mechanisms independent of exogenous antigen presentation.  
 
The etiology of RA is still unknown, although several hypotheses have been proposed; 
however, a strong genetic contribution to RA is well established. Within the Caucasian 
population, the most important genetic association is with the MHC locus -- specifically 
with HLA-DR4 and other closely related DR alleles [8]. One of the RA associated DR4 
alleles, HLA-DRB1 (*0401), may also be predictor of disease severity, with homozygous 




share a common motif near the peptide binding groove at residues 70-74 of the β chain 
[13-15]. When human HLA-DRB1 (*0401) is expressed as a transgene in mice, it confers 
susceptibility to induction of arthritis by immunization with certain autoantigens, even on 
otherwise genetically resistant backgrounds [16].  
 
Prior work has yielded mixed results regarding the capacity of fibroblasts to function as 
true APC for MHC-restricted responses to exogenous antigens from pathogens [17-20]. 
The present study sought to evaluate the ability of FLS to function as an antigen 
presenting cell (APC) for specific autoantigens present within the joint and relevant to 
RA. Mouse T cell hybridomas were employed that are specifically responsive to 
arthritogenic peptides of human cartilage gp39 (HCgp39, YKL-40) or human collagen II 
(hCII) presented by the human MHC II allele HLA-DRB1 (*0401), as measured by 
production of murine IL-2. These hybridomas were developed from a mouse transgenic 
for the human class II allele HLA-DR4 (*0401). Since these T cell hybridomas have been 
shown to recognize their respective antigens when presented by human dendritic cells or 
human monocytes which express *0401 [21], they were used to evaluate the APC 
potential of FLS for arthritogenic autoantigens. 
2-3. Methods 
Fibroblast isolation and culture 
All procedures involving specimens obtained from human subjects were performed under 
protocols approved by the University of Michigan Institutional Review Board. FLS were 
obtained by collagenase (Worthington Biochemical) digestion of human synovial tissue 




diagnosis was based upon the presence of at least 4 out of the 7 ACR criteria for RA [22]. 
The diagnosis of OA was based upon characteristic clinical and radiographic features, 
and confirmed by pathological findings at joint surgery. Cells were maintained in CMRL 
medium (Invitrogen) supplemented with 10% FCS (Atlanta Biological), 2mM glutamine 
(Cambrex), 50 U/mL penicillin (Cambrex), and 50µg/mL streptomycin (Cambrex). FLS 
were used after passage 4 from primary cultures.  
 
T cell hybridoma generation and culture 
T cell hybridomas specific for a 13 amino acid peptide of the arthritogenic human 
cartilage gp39 (HCgp39) and a 15 amino acid peptide from human collagen II (hCII) 
proteins (HCgp39 263-275 and hCII 259-273) were developed and characterized as 
previously described [21]. T cell hybridomas were cultured in RPMI medium 
(Invitrogen) supplemented with 10% FCS (Atlanta Biological), 2mM glutamine 
(Cambrex), 50 U/mL penicillin (Cambrex), 50µg/mL streptomycin (Cambrex), 0.6mM 




Peptide antigens RSFTLASSETGVG and GIAGFKGEQGPKGEP, corresponding to 
HCgp39 263-275 and hCII 259-273 respectively, were synthesized by the University of 
Michigan Protein Core.  Synovial fluid was obtained at therapeutic arthrocentesis, 
centrifuged to remove cells, and stored at -80 C for subsequent use. For testing of 




fluid/medium, for the HCgp39, or 20%/80% fluid/medium, for the hCII hybridoma, as an 
antigen source. FLS were incubated with antigens for between 3 to 7 days before addition 
of T cell hybridomas. Antigen incubation times less than 3 days resulted in suboptimal 
antigen presentation. 
 
FLS and T cell hybridoma co-culture. 
FLS were cultured with CMRL in 24 well plates at 10,000 cells per well and were 
allowed to adhere for 48 hours. FLS were then stimulated with 1000 U/mL IFNγ for an 
additional 48 hrs to re-induce MHC II, which is expressed in vivo by FLS. Four days 
after initial plating, the medium was changed and new medium containing 1000 U/mL 
IFNγ and 10ug/mL of peptide antigen (HCgp39 or hCII) was added for another 3 days. 
Seven days after initial plating, the medium was changed to T cell hybridoma medium, 
containing HCgp39 or hCII peptide at 10ug/mL. 200,000 T hybridoma cells were added 
while maintaining antigen concentration at 10ug/mL. T cells and FLS were allowed to 
interact for 3 days before plates were frozen and thawed. Plates were spun down and 
supernatants harvested. 
 
Mouse IL-2 ELISA 
ELISAs were performed using OptEIA Mouse IL-2 kits (BD Biosciences) and the 






DNA was isolated with the DNeasy Tissue Kit (Qiagen). MHC analysis used the HLA-
DR Typing Tray and DR 4T SSP Unitray (both Pel-Freez) to identify the presence of a 




For blocking assays, T cell hybridomas were incubated, before being co-cultured with 
FLS, in medium containing 10ug/mL anti-CD4, anti-CD11a, anti-CD2, or rat IgG. FLS 
were exposed to medium containing 10ug/mL anti-MHC II, anti-CD54, anti-CD58 or 
mouse IgG before the addition of T cell hybridomas. When cells were co-cultured, 
additional antibodies were added to maintain a final antibody concentration of 10ug/mL. 
 
HCgp39 ELISA 
ELISAs were performed using YKL-40 ELISA Kit (Quidel) and the manufacturer’s 
protocols were followed. 
 
2-4. Results 
FLS can present HCgp39 and hCII peptides 
To assess APC function of FLS, these cells were treated with IFNγ, loaded with 
immunodominant peptides from HCgp39 or hCII, and co-cultured with the HCgp39 or 
hCII specific T cell hybridoma. As a control the peptide and T cell hybridoma pairs were 




hybridoma). These mismatched peptide pairs are subsequently referred to as irrelevant 
peptide controls. The supernatants from these co-cultures were evaluated for murine IL-2 
as a measure of T cell stimulation due to FLS presentation of peptide antigen. FLS co-
cultured with the HCgp39 or hCII specific T cell hybridoma cells along with the cognate 
peptide induced significant release of IL-2 from the hybridomas (Figure 2-1A). When 
irrelevant peptide was presented, IL-2 production was greatly reduced. Hybridomas 
cultured with cognate peptide in the absence of FLS produced very little or no IL-2, 
indicating the requirement for an APC. 
 
To explore the effects of antigen concentration on the ability of FLS to activate T cell 
hybridomas, FLS were loaded with increasing concentrations of peptide antigen, ranging 
from 0.1ug/mL to 10ug/mL, and used as APC for T cell hybridomas. IL-2 production by 
the T cell hybridomas increased with the antigen concentration (Figure 2-1B). 
FLS APC function is dependent on IFNγ 
The requirement of IFNγ pretreatment for effective APC function by FLS was assessed. 
FLS, with or without IFNγ pretreatment, were cultured in medium containing HCgp39 
peptide antigen, and used as APC for the HCgp39 T cell hybridoma (Figure 2-1C). IFNγ 
pretreatment was necessary to reinduce expression of MHC II found in vivo [23]. IFNγ-
treated FLS were able to present antigen to T cell hybridomas, but FLS cultured without 
IFNγ did not function as APC. The IFNγ dependence of FLS APC function is consistent 




Fibroblast APC function is MHC II restricted 
Not all FLS lines were able to function as APC, even with IFNγ stimulation. It was 
hypothesized that lack of APC function by FLS was due to the MHC restriction of the T 
cell hybridoma response. Chromosomal DNA from various FLS lines, as well as from 
fibroblast lines from other tissue sources, were harvested and screened for HLA type by 
PCR. Using HLA-DRB1 (*0401) positive and DR4 negative FLS lines as APC for 
peptide antigens, we found that only *0401 positive cell lines could present antigen to the 
HCgp39 T cell hybridoma (Figure 2-2A). When a DR4 negative cell line was used as 
APC, no IL-2 was produced by the T cell hybridoma. 
 
We next sought to assess the DR4 subtype specificity of antigen presentation and also the 
antigen presentation potential of fibroblasts other than FLS. To address these issues, 
MHC typed lung fibroblasts cultured from interstitial pneumonia biopsies were treated 
with IFNγ, loaded with cognate antigen or irrelevant antigen, and used as APC. Similar to 
FLS, lung fibroblasts were able to load peptide antigen and present it to the HCgp39 T 
cell hybridoma (Figure 2-2B). Comparing *0401 positive, *0404 positive, and DR4 
negative lung fibroblast lines, this system showed stringent specificity for antigen 
recognition only in the context of *0401. Even the *0404 allele, which also contains the 
shared epitope and is associated with RA, did not function as an effective activation 
signal for the T cell hybridoma. The ability of fibroblasts to function as APC is therefore 
not unique to fibroblasts from a synovial source, and antigen presentation by fibroblasts 
of any tissue follows strict MHC restriction. Table 1 summarizes the results of HLA-DR 




fibroblasts used as APC. The ability of fibroblasts to act as APC corresponds strictly to 
possession of the correct MHC II subtype, specifically HLA-DRB1 (*0401), irrespective 
of the tissue source. Notably, DRB1 *0403 and *0404 expressing fibroblasts did not 
function as APC for the HCgp39 T cell hybridoma. Similar to professional APC, 
fibroblast APCs must express the MHC II allele with which T cells were educated. 
APC function is dependent upon MHC II and CD4 
Given that IFNγ is required to achieve effective APC function of FLS and MHC II 
restriction is displayed by T cell hybridomas and since IFNγ stimulation upregulates 
many proteins important for antigen presentation, the roles of Class II MHC and other 
structures important to T cell activation were further evaluated. We sought to isolate 
those critical to FLS/T cell interactions. Blocking antibodies were added to co-cultures of 
antigen loaded FLS and T cell hybridomas, including human MHC II, CD54, and CD58 
on the FLS surface and murine CD4, CD2, and CD11a on the T cell surface. Blockade of 
human MHC II or murine CD4 by antibody abolished the FLS activation of the HCgp39 
T cell hybridoma (Figure 2-3), and thus further demonstrated the importance of a 
functional peptide-MHC complex. Interference with human CD54 adhesion yielded less 
robust effects, and blockade of murine CD11a did not cause a similar reduction in IL-2 
production. Thus, it is unclear at this time whether a CD54-CD11a interaction is required 
for FLS to present antigen to T cell hybridomas. A CD58-CD2 interaction also does not 




FLS are also able to present autoantigens from synovial fluids 
To use a source of antigen more biologically relevant than synthetic peptides, human 
synovial fluids (SF) from RA and osteoarthritis (OA) patients were added to cultures of 
FLS. SF was collected from patients undergoing therapeutic arthrocentesis. Collected SF 
was centrifuged at 2000 rpm for 30 minutes to pellet synovial cells. The supernatant was 
used as an antigen source after being diluted to 20% in medium. FLS were able to extract 
hCII antigens from some SFs and activate the hCII T cell hybridoma (Figure 2-4A). One 
SF was able to elicit IL-2 responses that were comparable to 10ug/mL of peptide antigen 
(RA SF8). Other SFs (RA SF6 and OA SF3) were presented by FLS, but were not as 
potent as 10ug/mL of peptide antigen. FLS were unable to present antigen from some 
fluids. None of the fluids tested activated the hCII hybridoma in the absence of FLS; 
however, one fluid did activate the HCgp39 hybridoma minimally (data not shown). FLS 
presentation of antigens from SF was dependent on IFNγ pre-treatment, and antibody 
blocking studies revealed that APC function of FLS for SF antigens was MHC II 
dependent (data not shown). 
 
To assess whether the variability in the ability of different SFs to function as a source of 
antigen reflected the antigen concentration present within the fluid, various SFs were 
presented to the HCgp39 T cell hybridoma by FLS. The HCgp39 content within these 
fluids was measured by ELISA, and these SFs were diluted 50% in media and then 
loaded onto FLS for antigen presentation. The HCgp39 concentration was lower in SF 
than the amount of peptide used for antigen presentation. SF HCgp39 concentrations 




some SFs and activate T cell hybridomas (Figure 2-4B). Functional HCgp39 antigen was 
present in both RA and OA SF, similar to hCII antigen, as indicated by induction of IL-2. 
However, not all SF samples allowed FLS to activate hybridomas, even when HCgp39 
antigen was detectable by ELISA at concentrations similar to functionally presentable 
fluids. One fluid activated the HCgp39 hybridoma in the absence of FLS and was 
excluded (data not shown). 
 
The lack of correlation between antigen concentration in SF and the level of IL-2 
produced by the HCgp39 T cell hybridoma contrasted with previous results (Figure 2-
1B), which showed that the level of IL-2 produced by T cell hybridomas correlated with 
the concentration of peptide antigen presented. To explore this discrepancy we pooled the 
data from several experiments that measured the antigen concentration of SF and the 
ability of FLS to present HCgp39 from SF to the HCgp39 hybridoma. As an internal 
control, the resultant IL-2 response from these experiments was normalized as a 
percentage of the IL-2 response elicited by loading the same FLS lines with 10 ug/mL of 
synthetic peptide. This normalized response was plotted against the HCgp39 
concentration in the SF as measured by ELISA. A close correlation between the HCgp39 
concentration in SF and the amount of IL-2 produced by the HCgp39 specific T cell 
hybridoma was not observed (Figure 2-4C). Curve fitting analysis yielded a very low r2 
value of 0.0677. This result implies that other factors in SF regulate the capacity of FLS 






Presentation of autoantigens to T cells in synovial tissue could be very important in the 
initiation and perpetuation of inflammatory arthritis. The RA-associated MHC alleles 
possess a common sequence motif referred to as the “shared epitope” [13]. Structural 
analysis of the shared epitope region shows that it is positioned near the MHC peptide 
binding groove [15]; thus, influencing bound peptides or affecting interactions with T cell 
TCRs [14]. This suggests that antigen presentation may be an important pathogenic 
mechanism in RA. 
 
Previous data regarding fibroblasts as APC have been mixed. Early studies using dermal 
fibroblasts observed that they were poor generators of allogeneic responses [17]. This 
defect was not due to inadequate expression of MHC II, but was due to lack of an 
accessory molecule that could be provided by conventional APC. However, it was noted 
that dermal fibroblasts could stimulate previously activated alloreactive T cells. 
Expanding on this work, the capacity of dermal fibroblasts to function in antigen 
presentation was evaluated. Dermal fibroblasts were able to process antigen, but did not 
function well as APC without accessory cell help [18, 24]. In both of these studies IFNγ 
was used to induce MHC II, but autoantigens were not evaluated. These previous studies 
do document fibroblast expression of functional MHC II.  
 
FLS of RA synovium express high levels of MHC II in vivo and ex vivo [23], suggesting 
that the potential for antigen presentation by FLS in RA exists. Previous work indicated 




restricted mechanism [19]. Our current study expanded on these observations by 
examining the APC function of FLS for arthritogenic autoantigens, including endogenous 
proteins present in SF. 
 
There is also evidence that under some conditions FLS might not activate T cells, but 
instead induce anergy, in experiments that assessed the APC and allostimulatory 
functions of FLS [25]. In these studies, FLS were able to load antigen onto MHC II, but 
allogeneic responses depended upon the addition of accessory cells expressing CD80, and 
blockade of CD80 abolished the response (i.e. FLS are poor allogeneic stimulators 
similar to dermal fibroblasts [17]). When FLS without accessory cells were cultured with 
T cells, the T cells adopted a phenotype resembling anergy: upregulation of CD25, 
reduced proliferation, and reconstitution of proliferation by exogenous IL-2. This study 
implies that FLS cause anergy due to a lack of costimulatory molecules, but that 
bystander cells expressing co-stimulatory molecules could overcome this. The potential 
for accessory co-stimulation exists abundantly within RA synovium due to the close 
proximity of FLS to B cells, macrophages, and dendritic cells, as well as other T cells. 
 
The evidence that FLS can express functional MHC II is strong, but the function of FLS 
MHC expression has not been thoroughly explored. Work in transgenic mice suggests 
that the specific MHC II allele subtype has a striking effect on T cell polarization. 
Evaluation of the T cells from DR4 transgenic mice reveals functional differences 
between RA associated and non-associated alleles. T cells from *0401 transgenic mice, 




non-RA associated allele, by their cytokine profile after antigen stimulation. *0401 mice 
show a skew towards a Type I response and make greater levels of IFNγ and TNFα after 
stimulation with antigen compared to *0402 mice [20]. RA has been classified as a Type 
I disease and both of these cytokines are found within RA synovium. 
 
A possible reason for differing T cell responses to antigens presented by different DR4 
alleles is that the peptide binding repertoire of RA associated DR4 alleles is distinct from 
other DR4 alleles. HLA-DRB1 (*0401) presents immunodominant peptides from the 
autoantigens HCgp39 and hCII, which are peptides distinct from those presented by non-
RA DR4 alleles [20]. Perhaps, presentation of a unique panel of peptides by RA 
associated MHC activates a distinct set of T cells in the periphery and educates a 
corresponding set of T cells in the thymus, thus predisposing to autoimmunity [26, 27]. 
 
Even though a definitive autoantigen (or autoantigens) has yet to be consistently 
identified in this process of T cell development and activation in RA, HCgp39 and hCII 
are plausible candidates. These autoantigens are found within cartilage and synovial 
tissues, and are arthritogenic, able to induce inflammatory arthritis in susceptible strains 
of rodents [28]. HCgp39 is made by chondrocytes and macrophages, two cell types that 
are found in RA joints. Elevated serum HCgp39 appears to correlate to increased RA 
disease activity [29-31]. Peripheral blood mononuclear cells from RA patients show an 
increased proliferative response to HCgp39 antigen when compared to healthy controls 
[32]. The prevalence of HCgp39 responsive T cells in peripheral blood of RA patients 




IFNγ in response to HCgp39, whereas controls showed an IL-10 response, indicating that 
there is a skew towards inflammation in RA patients while controls show a regulatory 
response [34]. Histologic studies have even identified HCgp39 complexed with HLA-
DRB1 (*0401) on APC within human RA synovial tissue sections [35]. These 
observations support the idea that HCgp39 responsive T cell clones might contribute to 
RA pathogenesis or joint inflammation.  
 
Like HCgp39, hCII is a human autoantigen, also used to induce arthritis in mice, that 
serves as a model of RA [36]. It is only found within cartilage and synovial fluid or 
tissue. Although, autoantibodies towards hCII and hCII responsive T cell clones are not 
specific for RA [37], T cell clones in RA patients have been identified that have a TCR 
repertoire similar to hCII expanded T cells [38]. There is also evidence that T cell 
responses to altered forms of CII are important to RA [39]. Furthermore, co-cultures of 
hCII reactive T cells with FLS increased the production of IFNγ, IL-17, TNFα, IL-15 and 
IL18 [40]. These studies suggest that T cell responses are altered in RA patients such that 
responses to antigens might be skewed towards a pro-inflammatory response centered 
around HCgp39 and/or hCII antigens, even when measurable T cell proliferative 
responses are not remarkably elevated. 
 
In this current study HLA-DRB1 (*0401) positive FLS from different tissue sources were 
able to present immunodominant peptides from the arthritogenic proteins HCgp39 and 
hCII to antigen-specific T cell hybridomas. The key requirement appears to be the 




activated T cells, minimal co-stimulation may be needed for reactivation. Nonetheless, 
any activation of the T cell hybridoma indicates that a functional peptide-MHC II 
complex is present on the FLS. If irrelevant peptide or an MHC II mismatch is present, 
no T cell stimulation occurs. The significance of other structural interactions outside of 
MHC-TCR is not yet clear. The CD54-CD11a and CD58-CD2 interactions are often 
important for professional APC interaction with T cells. Inhibiting these interactions did 
not substantially disrupt FLS-APC function. Perhaps, cross-species limitations of some 
co-stimulatory receptor/ligand interactions and the relative lack of dependence of 
hybridomas on co-stimulatory signals minimize the roles of these molecules in the system 
that we used. 
 
FLS are also able to extract antigens from SF and present the antigens to both HCgp39 
and hCII T cell hybridomas. The exact nature of the antigenic material in SF is still 
unknown. It may include predigested peptide fragments and/or intact proteins, such as 
HCgp39. Whether these antigens are passively loaded onto FLS or externally taken up 
and processed remains to be discovered, and it is possible that both processes can occur.  
 
SF also contains many factors that could affect antigen presentation, enhancing or 
inhibiting it. This study did not find a correlation between the concentration of HCgp39 
in SF and the ability of FLS to present antigens to the HCgp39 T cell hybridoma. 
Inflammatory and inhibitory cytokines (e.g. IL-1 and IL-10) are present in SF, and may 
affect immune cell function. It is also possible that HCgp39 degradation products are 




fragmented portions of HCgp39 could result in a “functionally” high concentration of 
HCgp39, while leaving the measurable HCgp39 low. These issues will require further 
analysis in order to identify additional factors that govern FLS APC function in vitro and 
in vivo. 
 
FLS exist under unique conditions that provide mechanisms for activation or reactivation 
of T cells specific to arthritogenic autoantigens. FLS express high levels of MHC II in 
RA synovium and are chronically exposed to autoantigens present within SF. In the 
context of an inflamed RA joint, FLS could take up antigen, display antigenic peptides on 
MHC, and activate T cells in an antigen dependent mechanism as proposed by our in 
vitro studies. These T cells would either have been activated de novo within the 
synovium or previously activated in lymphoid tissues. The fact that RA FLS are 
surrounded by activated immune cells which express high levels of co-stimulatory 
molecules would further enhance T cell-FLS interactions through MHC II and TCR by 
cross-costimulation. APC function of FLS may be a hitherto overlooked mechanism of T 
cell activation in RA synovium. Moreover, the role of non-classical APCs, such as 


















Figure 2-1.  FLS present arthritogenic peptides to T cell hybridomas.  
A) FLS were plated and treated with IFNγ. HCgp39 or hCII peptides were pulsed onto 
FLS before they were co-cultured with T cell hybridomas. Mouse IL-2 was measured 
from culture supernatants from HCgp39 or hCII specific T cell hybridomas by ELISA. 
Error bars represent the range of the 95th % confidence intervals. B) FLS were pulsed 
with decreasing concentrations of HCgp39 peptide before coculture with the HCgp39 
specific hybridoma. C). FLS either received medium containing or devoid of IFNγ, 






































































































Figure 2-2.  MHC Restriction of antigen presentation by FLS 
A) HLA-DRB1 (*0401) positive and negative FLS lines were used to present peptide 
antigen to an HCgp39 T cell hybridoma. B) Arthritogenic peptide antigen presentation by 
FLS is restricted to HLA-DRB1 (*0401). Lung fibroblasts expressing the RA associated 
DR4 subtype alleles 0401 or 0404 were pulsed with HCgp39 peptide and co-cultured 
with the HCgp39 T cell hybridoma. IL-2 was measured from supernatants by ELISA. 




























































Figure 2-3.  APC function of FLS for peptide antigen responses of T cell hybridomas is 
MHC and CD4 dependent 
Blocking antibodies towards cell surface structures were added to co-cultures of FLS and 
the HCgp39 T cell hybridoma. Mouse IL-2 was measured by ELISA. Error bars represent 














































Figure 2-4.  FLS can extract antigen from SF and present it to HCgp39 and hCII T cell 
hybridomas. 
A) SF from RA and OA patients were diluted to 20% in medium and loaded onto FLS, 
before co-culture with the hCII specific T cell hybridoma. B) FLS were loaded with RA 
or OA SF diluted to 50% in medium before culture with the HCgp39 specific T cell 
hybridoma. The HCgp39 concentration within the SF was measured by ELISA and is 
indicated in the lower row beneath the graph. Error bars represent the 95th percentile 
confidence interval. C) OA or RA SF was loaded onto FLS and presented to the HCgp39 
T cell hybridoma. The resultant IL-2 production was represented as a percentage of the 
IL-2 produced from 10ug/mL of HCgp39 peptide and plotted on the y-axis. The x-axis 
displays the concentration of the HCgp39 antigen contained within SF. Linear regression 
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Table 1 MHC Typing of fibroblasts compared to antigen presenting activity. 
 
Type Line DR4 Subtype
APC 
Function 
04M098 0401 + 
04F115 0401 + 
RWS 0401 + 
CLC 0401 + 
04F096 0401 + 






RA77 none - 
100B 0401 + 
89A 0404 - 
Lu
ng
   
103B none - 
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3. Activation of Synovial Fibroblasts by Cytokine Activated T cells 
3-1. Summary 
Two striking features of RA synovium are cartilage-invading fibroblast-like synoviocytes 
(FLS) and a prominent T cell infiltrate. It is difficult to observe the in vivo interactions of 
these cells, but in vitro systems have documented bidirectional activation of both cell 
types. The current experiments were performed to more definitively analyze interactions 
between T cells and FLS at a molecular level, using imaging techniques and functional 
assays of FLS activation. Fluorescence confocal microscopy showed that the integrin 
LFA-1 localized to the contact point or “synapse” between T cells and FLS during the 
presentation of superantigen to T cells by FLS. When cytokine-activated T cells (Tck) are 
cultured with FLS (which have been shown to functionally mimic T cells isolated from 
RA synovial fluid), the synapse between Tck and FLS showed colocalzation of LFA-1 
and its counter-receptor, CD54/ICAM-1.  Cocultures of Tck with FLS resulted in contact-
dependent FLS production of IL-6 and IL-8, an effect that was synergistically enhanced 
by the T cell cytokine IL-17.   TNFα blockade inhibited Tck activation of FLS and 




culture supernatant. Surface blocking of TNFα inhibited similarly inhibited effector 
function of Tck and synergy with IL-17. These results implicate membrane-bound TNF 
in the Tck/FLS interaction, and provide an additional mechanism for the therapeutic 
utility of TNF blockade in RA. 
 
3-2. Introduction 
The normal synovial lining is one or two cell layers thick, contains both synovial 
macrophages and FLS, and is responsible for maintaining synovial fluid homeostasis. In 
RA, the synovial lining transforms into the synovial pannus, a multicellular tissue 
composed of FLS closely intertwined with invading lymphocytes and antigen presenting 
cells. The current consensus is that FLS are not merely bystanders in the inflammatory 
process, but are active participants in joint destruction [1-5]. However, the mechanism 
underlying this inflammatory transformation remains unknown. 
 
The most prominent invading lymphocyte in the RA synovium is the T cell [6-8]. The in 
vivo contribution of synovial T cells to RA etiology and pathology remains elusive, but 
in vitro studies have shown that T cells can adhere to and activate FLS. Functional 
studies have shown that FLS can present superantigen to naïve T cells, inducing a 
proliferative response [9], and peptide antigens to T cell hybridomas, inducing cytokine 
secretion (Chapter 2). Moreover, T cells can activate FLS to produce inflammatory 
mediators [10-12], and this is synergistically augmented by the T cell specific cytokine 





The current studies were undertaken to better define the molecular basis of T cell/FLS 
functional interactions. 
3-2. Methods 
FLS isolation and culture: 
All procedures involving specimens obtained from human subjects were performed under 
protocols approved by the University of Michigan Institutional Review Board. FLS were 
obtained by collagenase (Worthington Biochemical) digestion of human synovial tissue 
obtained at arthroplasty or synovectomy from RA or osteoarthritis (OA) joints. RA 
diagnosis was based upon the presence of at least 4 out of the 7 ACR criteria for RA [14]. 
The diagnosis of OA was based upon characteristic clinical and radiographic features, 
and confirmed by pathological findings at joint surgery. Cells were maintained in CMRL 
medium (Invitrogen) supplemented with 10% FCS (Atlanta Biological), 2mM glutamine 
(Cambrex), 50 U/mL penicillin (Cambrex), and 50µg/mL streptomycin (Cambrex). FLS 
were used after passage 4 from primary cultures.  
 
T cell generation: 
T cells were obtained from peripheral blood by negative selection using RosetteSep 
Human T cell Enrichment Cocktail (Stemcell Technologies) and separation on a Ficoll 
gradient. Briefly, freshly isolated blood from volunteers was incubated with kit antibody 
cocktail for 20 minutes at room temperature. Blood was diluted 1:1 with 2% NCS/PBS 
before overlay onto room temperature Ficoll, and spun at 1200 RCF with the brake off. 
The buffy coat containing only T cells was recovered and used for subsequent 




stimulated by a cocktail of 25 ng/ml TNFα, 100 ng/ml IL-6, and 25 ng/ml IL-2 for 8 days 
[15]. Tsea were T cells activated with the superantigen SEA (staphylococcal enterotoxin 
A) by coculture with IFNγ stimulated FLS [9]. 
 
Tck and FLS coculture. 
FLS were seeded into 12 well plates at a density of 10,000 per well and allowed to adhere 
for 48 hours before the addition of 250,000 Tck. IL-17 (R&D Systems) was added to 
cocultures to yield a final concentration of 20 ng/mL. Final culture volumes were 
1.5mL/well. Coculture times were between 24 and 72 hours depending on the assay. 
Coculture supernatants were harvest and assayed by ELISA. 
 
Confocal microscopy. 
20,000 – 50,000 FLS were grown on glass cover slips in 6 well plates for 48 hours. 
Media was changed and 500,000 – 1 million T cells (Trest, Tck, or Tsea) were added to 
the cultures. Cocultures were allowed to interact for 1 to 24 hours before cover slips were 
washed with PBS (Invitrogen) and fixed in 4% paraformaldehyde/PBS (Electron 
Microscopy Sciences) for 1 hour at room temperature or overnight at 4°C. For cocultures 
utilizing Tsea, after FLS were allowed to adhere for the initial 48 hours, they were 
stimulated with 1000 U/mL of IFNγ for an additional 48 hours. Subsequently, the IFNγ 
medium was changed to medium containing 1ng/mL of SEA (final concentration) before 
the addition of T cells. After fixation, cover slips were washed in 2%NCS/PBS to remove 
residual paraformaldehyde, and blocked in 5% nonfat milk/PBS for 30 minutes. 




were mouse anti-human CD11a [9] and mouse anti-human ICAM-1 (Clone 
R6.5.D6.E9.B2). Secondary antibodies used were goat anti-mouse IgG Alexa 594 
(Molecular Probes) and rabbit anti-goat IgG Alexa 488 (Molecular Probes).  For 
coculture studies comparing CD11a and ICAM-1 localization, before FLS were plated on 
glass coverslips they were transfected with an expression vector for a fusion protein of 
ICAM-1 and eGFP. This expression vector was termed CD54-eGFP and was created as 
follows. Primers were constructed against the sequence described by ascession 
BC015969 to PCR amplify the ORF (without the stop codon) of human ICAM-1. A 
HindIII restriction site at added to the beginning of 5’ primer and an AgeI site added to 
the tail of the 3’ primer facilitated ligation of the amplified fragment into the pEGFP-N1 
expression vector (Clonetech). After ligation the insert sequence was verified to be free 
of mutation. This resulted in a CD54-eGFP fusion protein expression vector, with ICAM-
1 at the N terminus and eGFP at the C terminus (intracellular) and a short peptide linker 
(GSTPVAT) in between. Transfection was carried out using the Adult Human Dermal 
Fibroblast Kit (Amaxa), and manufacturer’s protocols were observed. 
 
Transwell Assays. 
FLS were seeded into 12 well plates at a density of 10,000 per well and allowed to adhere 
for 48 hours. FLS location will subsequently be referred to as the bottom chamber. 
Transwell inserts with a 0.4 uM membrane pore size were placed on top of the wells 
containing FLS. These transwell inserts had been placed in medium for 24 hours before 
adding to plates containing FLS, to saturate the membrane. 500,000 Tck were added to 




1.5 mL. Total volume in the transwell was 0.5 mL. IL-17 was added to the transwell 
insert at 0.04, 0.4, and 4ng/mL concentration in 0.5mL, but would diffuse through the 
transwell to give a final concentration of 0.01, 0.1, and 1.0 ng/mL. 
 
Blocking studies 
FLS were seeded into 12 well plates at a density of 10,000 cells per well and allowed to 
adhere for 48 hours. Tck were incubated with one of two TNFα blocking antibodies from 
different clones (eBiosciences and R&D Systems) or control mouse IgG at 1 ug/mL for 
30 minutes at room temperature. 250,000 Tck were added to FLS containing wells with 
additional antibody to maintain a concentration of 1 ug/mL. IL-17 was titrated into 
cocultures in following concentrations: 0.02, 0.2, and 2.0 ng/mL (we found that 2 and 20 
ng/mL IL-17 synergized similarly with Tck, data not shown). Cocultures were 
maintained for 24 to 72 hours. 
 
3-4. Results 
Cytokine activated T cells induce FLS production of inflammatory cytokines 
Previous work in our laboratory utilized two types of T cells [9, 10]. Trest and Tsea could 
be viewed as representing polar states of T cell stimulation from naïve to full activation. 
An alternative state of T cell activation state has been described, termed cytokine 
activated T cells (Tck). Tck are generated through stimulation independent of the TCR 
with a cocktail of cytokines: TNFα, IL-6, and IL-2. These cytokines, in particular TNFα 
and IL-6, are found abundantly within synovial tissues. Tck have been documented to 




notably in the induction of TNFα from monocytes. The stimulatory mechanism of these 
cells is clearly distinct from T cells activated through CD3/CD28 cross-linking [15]. We 
sought to explore Tck effector function in T cell cocultures with FLS. 
 
FLS cultures were stimulated by the addition of Tck and allowed to interact for 36 hours. 
The cytokine IL-17, produced by RA synovial tissues [13], has been shown to synergize 
with Trest in the activation of FLS [10], and was also included in some wells. Three FLS 
lines were assayed for stimulation by Tck (Figure 3-1A and 3-1B). Tck stimulated FLS to 
produce the inflammatory cytokines IL-6 and IL-8, and this effector function synergized 
significantly with IL-17. No cytokine production was detected in cultures of Tck and IL-
17 in the absence of FLS (data not shown).  Imaging of Tck/FLS interactions revealed 
strong adhesion of Tck to monolayers of FLS (Figure 3-1C). Tck were found to adhere 
strongly to FLS by 1 hour of coculture, faster than Tsea or Trest (data not shown). 
Tck activation of FLS requires cell-cell contact 
The observed Tck effector functions on FLS were thought to require cell-cell contact, 
given that Tck-induced monocyte production of TNFα also required cellular interaction 
[15]. To explore the role of cell-cell contact, cocultures of Tck and FLS were set up using 
transwells. FLS were cocultured with Tck, and were either allowed to interact or Tck 
were separated from FLS by a transwell insert. The transwell insert allowed the free flow 
of cytokine, but prevented intercellular adhesive interactions to occur between FLS and 
Tck. IL-17 was added in increasing titrations directly into the transwell insert and 
allowed to diffuse through  the entire culture. Only when Tck were allowed to contact 




When Tck were separated from FLS by the transwell insert, IL-8 production was similar 
to IL-17 stimulation, best observed in the 1ng IL-17 column. This suggests that IL-17 
alone did cause Tck to produce soluble inflammatory mediators, which in turn could 
activate FLS. 
LFA-1 localizes to the contact between point FLS and Tsea and Tck 
Given that cell-cell contact is important for T cell interaction with FLS, we sought to 
explore the structures crucial to these interactions. There is evidence that the FLS-
adherent population of T cells expresses greater levels of the integrin LFA-1 [16]. It has 
also been observed that adhesion of T cells to FLS in static assays could be inhibited with 
blocking antibodies against LFA-1 (CD11a/CD18) and its counter-receptor ICAM-
1/CD54 [17, 18]. Beyond adhesion, LFA-1 has been implicated in supplying a 
costimulatory signal to T cells [19]. The adhesive and/or costimulatory properties of 
LFA-1 are important in the presentation of superantigens to T cells [20-22], and in 
particular superantigen presentation by FLS [9]. We therefore sought to define the 
contact point, or synapse, between FLS and T cells, and whether LFA-1 and ICAM-1 
colocalized in this region.  First we sought to define the localization of LFA-1 in an 
antigen dependent system. Cultures of FLS were treated with IFNγ and used as APC for 
the superantigen SEA to activate T cells. These cultures were fixed, stained for LFA-1, 
and examined by confocal microscopy. 3-D reconstruction of adherent Tsea, which had 
been stained with anti-CD11a antibody, showed that LFA-1 is arrayed in an asymmetric 
distribution and suggests LFA-1 intensity is greatest at the at the contact point between 





T cells can also interact with FLS independent of antigen presentation [10-12]. ICAM-1 
(CD54), the counter receptor to LFA-1, is an adhesion molecule expressed abundantly on 
the FLS surface [23]. In addition to adhesion, ICAM-1 ligation induces stimulatory 
signals in the cell that expresses this molecule [22, 24-26]. To observe the localization of 
ICAM-1 in antigen independent activation of FLS by Tck, FLS were transfected with an 
ICAM-1/eGFP fusion protein expression vector, termed CD54-eGFP, before coculture 
with Tck.  Cocultured cells were fixed and Tck were indirectly stained for CD11a by 
Alexa594. At the synapse of Tck and FLS, confocal imaging revealed merged signals 
between ICAM-1 and LFA-1 (Figure 3-4). Given the strong colocalization of ICAM-1 
and LFA-1 to the contact point of Tck and FLS, we attempted to disrupt the effector 
function of Tck on FLS using blocking antibodies to these adhesive proteins. 
Unexpectedly, blocking antibodies directed towards LFA-1 and ICAM-1 showed only 
modest inhibition of Tck effector function on FLS cytokine production (data not shown). 
 
TNFα is required for optimal Tck activation of FLS and synergy with IL-17 
A potent stimulatory molecule in RA is TNFα. Given the abundance of TNFα in RA 
synovial tissue and fluid [27, 28], and the use of TNFα blockade as an effective therapy 
for RA [29], the role of TNFα in Tck/FLS interactions was examined. Although, 
macrophages are considered to be the primary source of TNFα in RA, T cells are also 
known to produce TNFα [30]. Two different TNFα blocking antibodies were used to 
inhibit Tck/FLS interaction and Tck synergy with IL-17. TNFα blockade substantially 




production (Figure 3-5). However, TNFα inhibition did not affect IL-17 stimulation of 
FLS, indicating that IL-17 was not causing FLS to produce autocrine TNF. 
 
Based upon these findings, the TNFα concentration of coculture supernatants were 
evaluated by ELISA. No TNFα was detected from any of these cultures (data not shown). 
Since TNFα is initially expressed as a membrane bound protein and assuming membrane 
bound TNFα was responsible for TNFα effector function, Tck were preincubated with 
blocking antibody against TNFα for 30 minute and washed to remove excess antibody. 
These antibody-coated Tck were used to activate FLS. Preincubation of Tck with 
blocking antibody to TNFα significantly reduced Tck activation of FLS and synergy with 
IL-17, while Tck preincubated with control antibody did not inhibit activation of FLS 
(Figure 3-6A). To determine the expression of membrane TNFα, Tck were stained with 
the same antibody as was used to block TNFα function and examined by flow cytometry. 
Unexpectedly, the levels of membrane TNFα were not distinguishable above control 
antibody (Figure 3-6B). 
 
3-4. Discussion 
Accumulating evidence indicates that bidirectional signaling between T cells and FLS is 
robust and functionally significant. Several reports have documented T cell effector 
function towards FLS, resulting in augmentation of pro-inflammatory properties of FLS.  
Resting, unstimulated T cells have been shown to alter gene expression in FLS, and cause 
release of IL-6, IL-8, and PGE2 [10]. This effector function of resting T cells was not 




all had a similar capacity to activate FLS. T cells recovered from RA synovial fluid 
likewise elicit strong inflammatory responses when cultured with FLS, in particular 
strongly upregulating the immune modulating cytokine IL-15 [11]. As a prototype for 
autoreactive T cells that are potentially arthritogenic, collagen II stimulated T cells 
enhanced FLS production of many inflammatory mediators, and this effector function 
appeared to be proportional to the length of T cell activation with collagen [12]. 
Conversely, FLS have also been shown to positively stimulate T cells. Simple coculture 
of T cells with FLS enhances T cell survival and prevents apoptosis [31, 32]. More robust 
responses have also been reported. FLS can induce naive T cell proliferation by 
presentation of superantigen [9, 33]. When cocultured with FLS, T cells upregulate the 
activation markers CD69 and CD25 [11, 34], as well as many cytokines, such as IL-17, 
TNFα, and IFNγ [11, 12]. 
 
Our studies and work by others [11, 15] have demonstrated the importance of cell-cell 
contact for the bidirectional signaling of T cells for FLS and other cell types. Early 
experiments on T cell/FLS interaction noted that these cells readily adhered in coculture 
[16-18, 35]. The CD2/LFA-3 [35] and LFA-1/ICAM-1 [16-18] adhesive interactions 
have been implicated in T cell/FLS association. The relative requirements of these 
protein-protein interactions for T cell adhesion to FLS remains ill defined, as different 
studies report differing effects when these interactions were inhibited using blocking 
antibodies [17, 18, 35]. These differences were most likely due to the varying activation 
states of the T cells used, as well as differing methodologies used to assess adhesion. 




increased expression of LFA-1 and ICAM-1, respectively, on the adhesive population 
[16, 18]. Also, cell-cell interactions have been documented to positively signal in T cell-
FLS cocultures, leading to FLS upregulation of VCAM-1 and ICAM-1 [36]. We have 
been able to visualize LFA-1/ICAM-1 interactions between T cells and FLS by confocal 
microscopy and localize it to the contact point of the two cells. Specifically, we imaged 
the contact of point between FLS and T cells representative of two activation states: Tck 
and Tsea. Consistent with studies demonstrating the importance of LFA-1 for adhesion of 
T cells to FLS [16-18], LFA-1 localized to the contact point of Tsea and FLS during T 
cell stimulation by SEA. Also in systems devoid of exogenous antigens, using Tck cells 
that are activated independent of the TCR, LFA-1 could again be seen localized to the 
contact between Tck and FLS in conjunction with the counter-receptor ICAM-1 
expressed on the FLS surface. 
 
The signaling mechanisms between T cells and FLS involve a variety of mechanisms. 
The LFA-1/ICAM-1 interaction may play a role in this signaling beyond its role in 
adhesion. ICAM-1 [22, 24-26] and LFA-1 [19-21, 37, 38] have also been implicated as 
costimulatory structures that can enhance cellular activation. Clustering of LFA-1 to the 
contact sight between FLS and Tsea during presentation of SEA and colocalization of 
LFA-1/ICAM-1 at the synapse between Tck and FLS implied that activating signals 
could be conveyed by these proteins. A previous study reported that interference with this 
interaction could greatly blunt the outcome of T cell/FLS interactions [11]. 
Unexpectedly, in our system inhibition of LFA-1/ICAM-1 by blocking antibody only 




contribution of the LFA-1/ICAM-1 interaction in T cell adhesion assays to FLS, the 
overall contribution of this interaction to effector function of T cells in FLS activation 
depends on assay methodologies and T cell activation state.  
 
Beyond costimulation through adhesive molecules, many other pathways have been 
identified as activation mechanisms between T cells and FLS. The cytokine IL-15 has 
been identified as a mediator of T cell and FLS interactions [11]. Engagement of the 
costimulatory receptor CD40 on FLS by CD40L on activated T cells results in enhanced 
VEGF production [39]. The CD47/TSP-1 pathway has been shown to be involved in T 
cell adhesion and survival in cocultures with FLS [40]. 
 
Our study extends the repertoire of T cell/FLS interactions by focusing on the Tck, which 
are T cells that have been activated not through the TCR, but instead by a pool of 
cytokines similar to those found within RA synovium.  Tck have been shown induce 
TNFα production from monocytes through a mechanism distinct from pathways used by 
T cells stimulated through CD3/CD28 engagement, requiring NF-κB and inhibited by PI 
3-kinase [15]. Consequently, Tck provide a convenient in vitro system to generate T cells 
that function in a manner similar to RA synovial T cells. 
 
Tck proved to be potent activators of FLS, increasing production of IL-6 and IL-8 during 
cocultures. Similar to earlier experiments with resting T cells [10] and consistent with 
one of its proposed functions [41], IL-17 synergized with Tck. Based on previous reports 




1 and ICAM-1 would have more robust effects on Tck activation of FLS, but only 
marginal inhibition was observed. However, this effector function of Tck and synergy 
with IL-17 was dependent on cell-cell contact, and not due to basal cytokine production, 
as separation of Tck from FLS by transwell inserts abolished FLS stimulation.  
 
We explored TNFα as a potential signaling mechanism between T cell and FLS. TNFα is 
found abundantly within rheumatoid synovial tissues [27, 28, 42]. The binding of TNFα 
to one of its two distinct receptors [43, 44]results in many varied biological effects [45]. 
TNFα is initially synthesized as a transmembrane protein. Soluble TNFα is produced by 
shedding of the membrane bound form by the membrane-associated metalloproteinase 
TACE [46]. Membrane-bound TNFα is not simply a precursor of the fully functional 
cytokine. It has been reported to function in cytotoxic killing [47, 48]. It has been 
suggested that these two forms TNFα can mediate different biological effects [49, 50]. 
 
TNFα has been shown to be a potent proinflammatory signal for human FLS [51]. The 
first suggestion that TNFα might be contributing to the joint pathology seen in RA was 
with the creation of the mouse transgenic for human TNFα. This mouse developed a 
spontaneous inflammatory arthritis similar to RA, and was protected from this arthritis by 
TNFα neutralization [52]. In humans, in vitro cultures showed that synovial cell culture 
IL-1 production was inhibited by using TNFα blocking antibodies [53]. Ultimately, 





In view of the effective use of TNFα blockade in RA, and reports of IL-17 synergy with 
TNFα [41, 56], we explored TNFα blockade as an approach to inhibit Tck function.  
Anti-TNFα proved to be an effective inhibitor of Tck function and synergy with IL-17.  
In these experiments there was no evidence that IL-17 induced production of TNFα by 
FLS, as TNFα blocking antibody had no effect on IL-17 stimulation of FLS. We also 
found that, on Tck, TNFα is membrane bound, as indicated by the blocking effect on FLS 
activation seen with pre-coating of Tck with anti-TNFα, and by the lack of detectable 
soluble TNFα in the culture medium. The membrane bound TNFα on Tck could not be 
detected above background on Tck. This implies that even small amounts of membrane 
bound TNFα are effective inflammatory signals. It should also be noted that TNFα 
blockade greatly diminished Tck effector function and synergy with IL-17, effector 
function was not completely abrogated. This could be due to incomplete neutralization of 
all TNFα molecules, but is most likely due to the diverse signaling pathways between T 
cells and FLS that were not disrupted. 
 
Although the role of a T cell population expressiing membrane bound TNFα has not been 
well studied in RA pathophysiology, research in Crohn’s Disease (CD) has documented 
the pathologic functions of these cells. Similar to the dramatic results for RA, anti-TNFα 
therapy has proven to be an effective treatment for CD [57, 58]. In determining the 
mechanism of this therapeutic effect, it was found that neutralization of TNFα resulted in 
lowered IFNγ and TNFα production from CD patient T cells [59-61]. Further study 
revealed that therapeutic anti-TNFα monoclonal antibodies exerted their effects by 




caspase-3 activation and apoptosis in cell cultures, with intestinal lamina propria T cells 
showing increased susceptibility compared to peripheral blood T cells [62]. This 
apoptotic effect was further verified by endoscopic tissue biopsy of CD patients receiving 
anti-TNFα therapy for T cell death [63].  
 
In our studies, we have used a population of T cells which resemble T cells isolated from 
RA SF to activate FLS. Similar to T cells from CD these Tck utilize membrane bound 
TNFα as a mechanism to convey inflammatory signals. This suggests that along with 
soluble TNFα, TNF on T cell surfaces could be an important signaling interaction in RA. 
These results provide another mechanism for the utility of TNF blockade in the treatment 



















Figure 3-1. Tck adhere to and activate FLS. 
Tck were cocultured with three different FLS lines and the resultant IL-8 A) and IL-6 B) 
in culture supernatants were measured by ELISA. Error bars represent the 95% 
confidence interval. C) FLS were grown on glass coverslips and cocultured with Tck. 





























































Figure 3-2. Tck stimulation of FLS requires cell-cell contact. 
FLS were grown in the bottom chamber of a transwell assay plate. Tck were added 
directly into the bottom chamber with FLS (+Tck) or above FLS separated by transwell 
inserts ([+Tck]). IL-17 was titrated into the transwell inserts to diffuse throughout the 
cocultures. The resultant IL-8 production in supernatants was measured by ELSIA. 
Brakets ([]) denote additions inside the transwell and not directly to FLS. Error bars 
























































Figure 3-3. LFA-1 localizes to the contact point between Tsea and FLS. 
IFNγ stimulated FLS were grown on glass coverslips and used to present superantigen to 
Tsea. Confocal slices of a Tsea adhering to an FLS were reconstructed to form a 3-D 
image of LFA-1 distribution on the Tsea. This 3-D reconstruction was rotated and 3 




































Figure 3-4. LFA-1 and ICAM-1 colocalize to the contact point between Tck and FLS. 
FLS were transfected with an expression vector for CD54-eGFP fusion protein before 
being cocultured with Tck. Localization of LFA-1 on Tck surfaces was stained (red) and 
compared to ICAM-1 (green) on the FLS. Confocal imaging of stained cocultured cells 
was performed to examine cell-cell interactions. Merged signals where LFA-1 and 
ICAM-1 colocalize appear yellow. Top row: 60X magnification of a CD54-eGFP 
transfected FLS with many Tck adhered. Middle and bottom rows: Digitally zoomed 

































Figure 3-5. Tck activation of FLS requires TNFα. 
IL-8 production from three different cellular cultures was compared: Tck cultured alone 
(Tck alone), FLS cultured alone (FLS alone), or FLS cultured with Tck (FLS+Tck). 
Before coculture with FLS, Tck were incubated with either one of two different TNFα 
blocking antibodies (anti-TNFα #1 or anti-TNFα #2), control antibody (MsIg), or no 
antibody (Media). The concentration of antibody in cocultures was kept constant. The 
resultant IL-8 production from different conditions is represented by a 3-D chart. The x-
axis displays culture conditions with blocking antibodies used. The y-axis shows IL-8 
production. The z-axis shows the concentration of IL-17 titrated into the cultures and is 
also represented by increasing color density of blue for the graphed columns, ranging 






























Figure 3-6. Tck activation of FLS requires TNFα that is membrane bound. 
A) Tck were incubated with TNFα blocking antibody for 30 minutes to bind all surface 
TNFα. Excess blocking antibody was removed by pelleting and sequential washes of Tck 
with PBS before coculture with FLS (pre anti-TNFα). As a controls, Tck were also 
similarly pre-blocked with mouse IgG (preMsIg) or TNFα neutralizing antibody was 
directly added to cocultures with FLS and Tck without removal of excess antibody (MsIg 
or anti-TNF respectively). The effects of these antibody regimes were compared using 
stimulation by Tck and Tck+IL-17. IL-8 production was measured by ELISA. Error bars 
represent the 95% confidence interval. B)  Tck were generated by culture with cytokines 
and stained with control antibody (MsIg), anti-human CD3, or with anti-human TNFα. 
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4. Fibroblast-Like Synoviocytes Express the B7 Family Costimulatory Molecule B7-H3 
4-1. Summary 
FLS and T cells can activate each other in vitro, and in vivo interactions between these 
cells may be important in the pathogenesis of RA. However, FLS lack significant 
expression of the ligands for CD28, the prototypic T cell costimulatory receptor.  We 
sought to identify other molecules homologous to CD28 ligands that would be more 
strongly expressed by FLS, such as the molecule termed B7-H3. By flow cytometry we 
documented strong B7-H3 expression on FLS, which was unaffected by the cytokines 
IFNγ, IL-4, IL-10, IL-17, IL-1β, or TNFα. Western blot analysis was employed to 
identify the specific isoforms of the B7-H3 expressed by FLS, and showed predominant 
expression of the larger, 4-Ig-domain isoform of B7-H3.  Immunohistochemical staining 
of RA synovial tissue revealed substantial expression of B7-H3 in vivo, and B7-H3 
expression patterns were similar to fibroblast specific markers Cadherin-11 and CD90. 
These sections also showed that B7-H3 was distinct from but in close proximity to cells 
that expressed CD45, CD20, and CD3. Confocal microscopy of FLS and T cell 




but distinct from the localization of  T cell CD11a (LFA-1) and FLS CD54 (ICAM-1). 
RNA interference was used to knock down B7-H3 expression in FLS and these FLS were 
cocultured with T cells to observe the effect on T cell cytokine production. Some T cells 
that were cultured with B7-H3 knock down FLS had reduced or enhanced cytokine 
production depending upon the activation state of the T cell. These observations suggest 
that B7-H3 may be important in the interactions between FLS and T cells in RA, and 
potentially other diseases. 
 
4-2. Introduction 
The RA synovial environment comprises a complex mix of cell types. Invading 
lymphocytes are in close proximity to resident structural cells. In this milieu, particular 
focus has turned to the interaction between the most numerous lymphocyte, the T cell, 
and the structural cell which invades cartilage, the FLS [1-4]. 
 
In vitro assays have documented strong association and bidirectional signaling between 
these two cell types. Similar to professional APC-T cell interactions, FLS and T cells in 
co-cultures have been shown to interact in antigen dependent systems. FLS can present 
superantigen to T cells inducing a proliferative response [2]. FLS are also able to take up 
and present arthritogenic peptide autoantigens to HLA-DR4 restricted T cell hybridomas 
[5]. Moreover, T cells previously stimulated by antigen presented by professional APC 
have augmented ability to interact with FLS, leading to increased release of IL-15, TNFα, 





T cells and FLS can also interact and signal in the absence of exogenous antigen. Naïve T 
cells cultured with FLS cause FLS to increase production of inflammatory mediators such 
as IL-6, IL-8, and PGE2 [4]. Conversely, T cells have been reported to express the 
activation marker CD69 after co-culture with FLS [1]. 
 
FLS share features in common with professional APC, and they express many surface 
glycoproteins related to lymphocyte trafficking and signaling, such as VCAM-1 and 
CD54 [7]. The integrin CD11a/CD18 (LFA-1) clusters at the contact point between T cell 
and FLS [8], and T cell adherence to FLS is inhibited by blocking antibody to LFA-1 [9]. 
FLS also express significant MHC II in vivo [10], which can be reinduced in vitro [11, 
12]. However, unlike traditional APC, FLS do not express the classic costimulatory 
molecules B7-1 or B7-2 (CD80, CD86) [13, 14], which typically provide the second 
signal for full T cell activation. 
 
A family of B7 related proteins has been discovered that have variable homology to 
CD80 or CD86. One of these proteins is termed B7-H3, a type I transmembrane protein 
with approximately 20% sequence homology to B7-1, B7-2, PD-L1, and ICOS-L [15]. 
Human B7-H3 was initially described as a costimulatory molecule expressed only on 
some activated APC and lymphocytes. Ligation of B7-H3 to a putative receptor on 
activated T cells enhanced proliferation and IFNγ production. Further genomic analysis 
of B7-H3, in human and mouse, revealed that the human form can be expressed as two 
distinct isoforms while the mouse expresses only one isoform [16-18]. The human B7-H3 




containing either four Ig-like (4IgB7-H3, B7-H3b)or two Ig-like (2IgB7-H3, B7-H3) 
domains. The mouse gene only contains two Ig-like repeats, and thus only one form is 
expressed.  
 
Similar to the other B7 family members, subsequent studies have shown that B7-H3 can 
mediate inhibitory effects [17, 19, 20] on T cell function as well as costimulatory effects 
[15, 21-23]. Unlike B7-1 and B7-2, B7-H3 has been shown to also be expressed on non-
hematopoietic cells [17]. Although FLS lack expression of the classic costimulatory 
molecules B7-1 and B7-2, we hypothesized that FLS might express other costimulatory 




FLS isolation and culture 
All procedures involving specimens obtained from human subjects were performed under 
a protocol approved by the University of Michigan Institutional Review Board. FLS were 
obtained by collagenase (Worthington Biochemical) digestion of human synovial tissue 
obtained at arthroplasty or synovectomy from RA or osteoarthritis (OA) joints. RA 
diagnosis was based upon the presence of at least 4 out of the 7 American College of 
Rheumatology criteria for RA [24]. The diagnosis of OA was based upon characteristic 
clinical and radiographic features, and confirmed by pathological findings at joint 
surgery. Cells were maintained in CMRL medium (Invitrogen) supplemented with 10% 




and 50µg/mL streptomycin (Cambrex). FLS were used after passage 4 from primary 
cultures.  
 
T cell generation 
T cells were obtained from peripheral blood by negative selection using RosetteSep 
Human T cell Enrichment Cocktail (Stemcell Technologies) and separation on a Ficoll 
gradient. Briefly, freshly isolated blood from volunteers was incubated with kit antibody 
cocktail for 20 minutes at room temperature. Blood was diluted 1:1 with 2% NCS/PBS 
before overlay onto room temperature Ficoll, and spun at 1200 RCF with the brake off. 
The buffy coat containing only T cells was recovered and used for subsequent 
experiments. T cells were maintained in RPMI (Cambrex) supplemented with 10% FCS 
(Atlanta Biological), 2mM glutamine (Cambrex), 50 U/mL penicillin (Cambrex), and 50 
ug/mL streptomycin (Cambrex). Trest were resting T cells that had been freshly isolated. 
Tck were cytokine activated T cells stimulated by a cocktail of  25 ng/ml TNFα, 100 
ng/ml IL-6, and 25 ng/ml IL-2 for 8 days [25]. Tsea were T cells activated with 
superantigen SEA (staphylococcal enterotoxin A) 10 ng/mL by co-culture with IFNγ 
stimulated FLS [2]. TCD3 were T cells stimulated by plates coated with a combination of 
10 ug/mL mouse anti-human CD3 and 10 ug/mL mouse anti-human CD28 for 8 days. 
 
Flow cytometry 
Fibroblasts were grown for 48 hours in plates before stimulation with cytokines: IFNγ 
1000U/mL, TNFα 10ng/mL, IL-1β 1ng/mL, IL-17 20ng/mL, IL-10 10ng/mL, or IL-4 




plates for staining by incubation with 3mM EDTA in PBS for 20 minutes at room 
temperature. Cells were stained with mouse anti-human antibodies towards CD98, CD54, 
or B7-H3 (R&D Systems), or with a mouse IgG control. A secondary goat anti-mouse 
IgG Alexa488 (Molecular Probes, Invitrogen) conjugate was used to visualize 
fluorescence. Cytometry was performed on a Coulter EPICS XL. 
 
Western Blot 
Western blot analysis used standard protocols. Fibroblasts were grown in 175 cm2 flasks 
to confluence and lysed with a buffer containing 1mM PMSF, 5mM iodoacetamide, 8mM 
Tris-HCl, 100mM NaCl, 0.02% NaN3, and 1% NP-40 or 1% saponin as the primary 
detergent. Preclearing steps were: 1)  25 uL protein-G agarose beads (Invitrogen), 2) 1 ug 
mouse IgG (Sigma) followed by 25 uL protein-G agarose, and 3) 1 ug goat IgG 
(Antibodies Inc) followed by two rounds of 25 uL protein-G agarose.  Lysates were run 
in reducing buffer on Tris-Glycine 4-20% acrylamide gradient gels (Novex, Invitrogen) 
and transferred onto an Immobilon-P membrane (Millipore). Primary antibody, goat anti-
human B7-H3 (R&D Systems), was used at a concentration of 1 ug/mL for 1 hour at 4 
°C. Control goat IgG antibody (Sigma) was also used at 1ug/mL. Membranes were 
washed 3 times with wash buffer before development with rabbit-anti-goat-HRP 
conjugate (Molecular Probes, Invitrogen) at 0.2ug/mL for 1 hour at 4 °C. Membranes 
were developed by ECL (Amersham).  
 
Immunohistochemistry 




sections were mounted onto glass slides. Immunohistochemistry was performed using 
standard protocols for dichromatic staining of frozen and paraffin embedded sections 
[26]. Goat anti-human antibodies were anti-B7-H3 (R & D systems), biotinylated anti-
B7-H3 (R & D systems), anti-CD90 (insert manufacturer), and anti-cadherin-11 (R & D 
systems). Mouse anti-human antibodies were anti-CD3 (R& D Systems), anti-CD68 
(Dako Cytomation), anti-CD20 (Signet Laboratories), anti-CD45 (Signet Laboratories), 
and anti-cadherin-11 (Zymed). Detection antibodies and secondary detection reagents 
used were biotinylated horse anti-goat IgG (Vector Laboratories), alkaline phosphatase 
horse anti-mouse IgG (Vector Laboratories), R.T.U. VECTASTAIN Elite ABC Reagent 
(Vector Laboratories), Vector Blue Substrate (Vector Laboratories), Vector Red 
Substrate (Vector Laboratories), and AEC substrate (Vector Laboratories). After staining 
sections were sealed using Faramount.  
 
Confocal Microscopy 
FLS were grown on glass coverslips for 48 hours. Trest, Tck, or Tsea were co-cultured 
with FLS for various time points. Coverslips were then washed with PBS and fixed in 4% 
paraformaldehyde (Molecular Probes) for 1 hour at room temperature or overnight at 4 
°C.  Coverslips were stained using goat anti-human B7-H3 (R&D Systems), mouse anti-
human CD11a, mouse anti-human CD54. Secondary antibodies used were goat anti-
mouse IgG Alexa594 and rabbit anti-goat IgG Alexa488.  For co-culture studies 
comparing LFA-1 and ICAM-1 localization, before FLS were plated on glass coverslips 
they were transfected with an expression vector for a fusion protein of ICAM-1 and 





B7-H3 Knockdown and Co-culture of T cells  and FLS 
Three stealth RNAi and two control RNAi were obtained from Invitrogen algorithms 
based against the sequence accession AJ583695 from GenBank. Stealth RNAi's were 
pooled in equimolar amounts and used at a working concentration of 10 uM, to knock 
down B7-H3 expression. Control RNAi  was also pooled in equimolar amounts and used 
at a working concentration of 10 uM. FLS were transfected with RNAi using the adult 
human dermal fibroblast kit (Amaxa Systems). For transfection, FLS were removed from 
plates by trypsinization and pelleted. FLS were then resuspended in transfection buffer 
with 1-5 uM final concentration of RNAi and placed in cuvettes. FLS were electroporated 
and replated for 48 hours before use. As an additional control, FLS were mock 
transfected without the use of RNAi. Transfected FLS were allowed to rest for 48 hours 
before being seeded onto plates. FLS were left to adhere for an additional 48 hours after 
seeding. To evaluate the effect of FLS on T cell cytokine production, Trest, Tck, or TCD3 
were then added to FLS at a ratio of 1:6.66 FLS to T cells. After 8 days, T cells were 
collected from co-cultures by gentle washing with media. Harvested T cells were washed 
twice in media and then replated at 500,000 cells in 1.5 mL of medium. T cells were then 
stimulated for 12 hours with 10 ng/mL PMA and 0.5 uM ionomycin. Supernatants were 
harvested and TNFα, IFNγ, and IL-2 levels were measured by ELISA (BD Biosciences). 
 
4-4. Results 
B7-H3 is expressed by FLS and other fibroblasts 




stimulated cells (Figure 4-1A). In contrast, the B7 family member ICOS-L (B7-H2) was 
not detected (Figure 4-1A). Expression of B7-1 or B7-2 (CD80 and CD86 respectively) 
by FLS was previously reported to be negligible [13, 14]. Similar to ICOS-L expression, 
B7-H1 and PD-L2 expression was negligible on FLS and did not increase with IFNγ 
stimulation (Figure 4-1B). To assess whether other fibroblasts also selectively expressed 
B7-H3 and whether immunoregulatory cytokines affected B7-H3 expression, we 
compared B7-H3 expression on RA FLS, OA FLS, skin fibroblasts, and lung fibroblasts. 
These various fibroblasts were stimulated, before surface staining, with various 
immunoregulatory cytokines for 72 hours, including IFNγ, TNFα, IL-1β, and IL-17. As a 
control, CD54 (ICAM-1) expression was also measured. All four types of fibroblasts (RA 
FLS, OA FLS, skin, and lung) expressed high basal levels of B7-H3, which was 
unaffected by cytokine stimulation (Figure 4-2). In contrast, CD54 expression increased 
or decreased depending on the cell type and cytokine (Figure 4-2). 
 
B7-H3 expressed by FLS and other fibroblasts is predominantly 4Ig 
Since human B7-H3 can be alternatively spliced to yield  4IgB7-H3 (B7-H3b) or 2IgB7-
H3 (B7-H3), western blot analysis was used to determine the molecular weight of B7-H3 
expressed by fibroblasts. We first established that the antibody employed for western blot 
analysis recognized both isoforms of B7-H3, detecting a band at slightly less than 98 kDa 
for recombinant 4IgB7-H3 and slightly less than 50 kDa for 2IgB7-H3 (Figure 4-3A). 
 
Whole cell lysate, from RA FLS lysed in NP-40 was precleared, separated by SDS-




approximately 110 kDa corresponding to glycosylated 4IgB7-H3. Extending the blot 
development time to 3 hours did not reveal the presence of a 2IgB7-H3 band near 50 
kDa, but nonspecific background staining was visible (Figure 4-3B). 
 
To determine whether OA FLS or fibroblasts from skin and lung also predominantly 
express 4IgB7-H3, western blot analysis was again employed. Whole cell lysates from 
RA FLS, OA FLS, skin fibroblasts, or lung fibroblasts were created using saponin as the 
detergent, (which resulted in better recovery of B7-H3 compared to NP-40, data not 
shown). To minimize any potential loss of 2IgB7-H3 signal, this lysate was not 
precleared before separation on SDS-PAGE. Blot development yielded a strong band at 
110 kDa for all fibroblast types and a much weaker band at approximately 50 kDa 
(Figure 4-3C). This suggests that the 4Ig isoform is the major and almost exclusive 
isoform of B7-H3 expressed on fibroblasts. 
 
B7-H3 is broadly expressed in RA synovium. 
To evaluate the expression of B7-H3 in vivo, synovium was obtained from arthroplasty 
or synovectomy of RA joints, and immediately fixed in formalin for embedding in 
paraffin, or frozen in OCT. To locate regions rich in FLS, RA synovial sections were 
stained with the FLS specific anti-cadherin-11 (Cad-11), which was compared to B7-H3 
staining (Figure 4-4A).  Cadherin-11 is used by FLS in homotypic adhesive interactions, 
is expressed by synovial lining FLS, and is important for the overall morphology and 
development of the synovial lining [27]. Monochromatic staining of B7-H3 or Cad-11 




H3 was to the lining layer of RA synovium, however, Cad-11/B7-H3 was also found 
diffusely throughout synovial tissue (Figure 4-4A). CD90, another fibroblast marker, was 
used to show the diffuse expansion of FLS in RA synovium, but unlike Cad-11/B7-H3, 
CD90 localized strongest to blood vessel rich reasons (Figure 4-4A). This is strong 
indication that, similar to cultured FLS, the FLS in RA synovium express B7-H3. 
 
Dichromatic immunohistochemical staining was performed, to compare the expression of 
B7-H3 to immune cell markers. Staining of paraffin sections for B7-H3 and CD20 (B 
cell), CD45 (hematopoietic), or CD68 (macrophage) surface structures revealed that B7-
H3 staining was distinct from CD20 and CD45 (Figure 4-4B). There was diffuse B7-H3 
expression throughout the pannus with slightly stronger localization towards the lining 
layer and around blood vessels. Patches of B cells and hematopoietic cells appeared 
distinct from the B7-H3+ cells. The macrophage marker CD68 showed broad staining 
that overlapped partially with B7-H3 expression. This most likely represents resident 
macrophage-like synoviocytes and invading macrophages. The control antibody for B7-
H3 (goat IgG) displayed only a background staining pattern (Figure 4-4B). Frozen 
sections were stained to compare B7-H3 staining to CD3 (T cell) or CD80 (APC) staining 
(Figure 4-4C). CD3+ T cells were abundant and in close proximity to B7-H3+ cells. 
CD80 staining showed a diffuse pattern, indicating the broad distribution of professional 
APC within the synovium. However, at the synovial lining, B7-H3 staining was strong 
and there was little CD80 signal. 
 




throughout RA synovial lesions. However, since B7-H3 is not unique to FLS, CD3 
staining was compared to Cad-11 and CD90 (Figure 4-4D). Similar to the pattern seen 
with B7-H3/CD3 (Figure 4-4C), Cad-11/CD3 and CD90/CD3 staining showed both well-
organized and diffuse T cell regions, with many T cells in close proximity to Cad-11+ 
FLS (Figure 4-4D).  
 
B7-H3 localizes to the contact point between FLS and T cells. 
T cells representing three different T cell activation states were co-cultured with FLS. 
Tsea were T cells that had been stimulated through their TCR by superantigen presented 
by FLS. Cytokine activated T cells (Tck) were activated with a cytokine cocktail, (and 
not by the TCR), consisting of IL-6, TNFα, and IL-2, and represent a population that 
share characteristics similar to T cells isolated from RA synovial fluid [25]. Trest were T 
cells that were purified from peripheral blood and not otherwise stimulated. After 2 or 24 
hours, the co-cultures were fixed with paraformaldehyde and stained for B7-H3 and CD3. 
By 24 hours, B7-H3 signal could be seen outlining the contact point of both Tck and Tsea 
on FLS (Figure 4-5A&B). At 24 hours, Trest adherence to FLS was marked, but strong 
B7-H3 signal at the contact site was not clearly visible (Figure 4-5A). This localization of 
B7-H3 to the contact region with Tck and Tsea on FLS is clearly distinct as early as 2 
hours of co-culture (Figure 4-5B). 
B7H3 localization at the FLS/Tck point contact is distinct from the zone of CD54/LFA-1 
engagement. 




counter receptor, LFA-1 (CD11a/CD18), on the T cell. FLS were transfected with a 
CD54-eGFP (green) expression vector before co-culture with Tck.  Co-cultured cells 
were fixed and Tck were indirectly stained for CD11a which was visualized by means of 
the fluorochrome Alexa594 (red). At the synapse of Tck and FLS, confocal imaging 
revealed merged signals (yellow) between CD54 and LFA-1 (Figure 4-6A).  In contrast, 
B7-H3 at the FLS/Tck contact point showed a staining pattern that was distinct from 
CD54 (Figure 4-6B), as seen by the separation of green and red signals. Similarly no 
merging of B7-H3 and LFA-1 fluorescence was detected (Figure 4-6C). The separation 
of B7-H3 from regions dense in LFA-1/CD54 at the contact point between FLS and Tck 
could be a temporal artifact. It is possible that B7-H3 might migrate to and from 
LFA/CD54 dense areas in a rapid sequence or at extremely slow rate not detected by the 
time points of confocal image. However, we have not observed any merged signal of B7-
H3 with LFA-1 or CD54 at co-culture times up to 24 hours (data not shown). 
Distinct functions of B7-H3 in interactions with resting versus cytokine activated T cells 
To assess the role of B7-H3 in co-cultures of T cells and FLS, RNA interference (RNAi) 
technology was used to knock down B7-H3 expression in FLS before co-culture with T 
cells. Pools of specific or control RNAi's were transfected into FLS and screened for 
effective inhibition of B7-H3. Effective and specific knockdown of B7-H3 persisted for 
at least 12 days post-transfection (Figure 4-7). RNAi transfection did not adversely affect 
CD98 expression in mock transfected or RNAi transfected FLS (Figure 4-7). 
 
T cells representative of three activation states were co-cultured with FLS: Trest were 




similar to RA synovial T cells [25]; TCD3 were T cells that had been previously activated 
through plate bound anti-CD3/anti-CD28. TCD3 were used in place of Tsea to represent 
TCR stimulated T cells in these experiments, to avoid the need for exposure of T cells to 
APC prior to incubation with B7-H3 knockdown FLS, which could potentially confound 
interpretation of the results. These various types of T cells were co-cultured with FLS 
that had been transfected with pooled B7-H3 RNAi, pooled control RNAi, or mock 
transfected FLS (no RNAi). After 8 days of co-culture with B7-H3 knockdown FLS, T 
cells were harvested and restimulated with PMA and ionomycin for 12 hours. Production 
of TNFα, IFNγ, and IL-2 by the T cells was measured by ELISA. While cytokine 
production by TCD3 following co-culture with FLS was not substantially affected by B7-
H3 knockdown, striking and opposite effects on cytokine production of Tck and Trest 
were observed. Trest co-cultured with B7-H3 negative FLS showed increased levels of 
cytokine production compared to FLS transfected with control RNAi (Figure 4-8A to C). 
In contrast, Tck co-cultured with B7-H3 negative FLS showed reduced cytokine 
production compared to co-culture with control RNAi FLS (Figure 4-8A to C). This 
suggests that B7-H3 has an inhibitory effect on Trest and a stimulatory effect on Tck. 
 
4-5 Discussion 
B7-H3: inhibitory or costimulatory? 
To achieve full activation during the response to peptide antigens, T cells require two 
stimulatory signals. TCR engagement of MHC/antigen triggers complex signaling 
cascades in T cells, but alone this is insufficient for activation [28-31]. A costimulatory 




prevent anergy. This additional signal to the TCR is typically provided by a surface 
structure present on accessory cells, such as B7-1 (CD80), which can engage the CD28 
molecule on the T cell surface [32-36]. The discovery of a second receptor for B7, 
CTLA-4, which is important in limiting T cell responses, established a molecular basis 
for the bifunctional role of B7 as both an activating and inhibitory ligand [37].  
 
Starting from the initial B7-1 costimulatory ligand, a family of B7 molecules has been 
discovered. B7-2 (B70, CD86) is a second ligand for both CD28 and CTLA-4. New 
ligand/receptor pairs include PD-L1 (B7-H1)/PD-1, PD-L2 (B7-DC)/PD-1, ICOS-L (B7-
H2, B7h, B7RP-1)/ICOS, and B7-H4/BTLA [38-40]. These novel B7 family molecules 
have documented effects in enhancing T cell functions, inhibiting T cell functions, or 
both.  
 
This duality is further reinforced by the more recent characterization of the B7 related 
protein VSIG4. Initially, VSIG4 (CRIg) was described as a complement receptor 
necessary for binding enzymatic products of C3 and for effective phagocytosis by 
Kupffer cells [41]. In addition, VSIG4 has been also been found to reduce T cell 
proliferation by CD3/CD28 stimulation in vitro, and to blunt CD8 T cell responses and 
IFNγ production in vivo [42].This complex pattern of inhibition and/or activation is an 
important characteristic of the B7 family. Thus beyond the their role in immune 
activation, the B7 family functions in the complex realm of immune modulation [38-40]. 
This is exemplified by the discoveries that CD28 and CTLA-4 not only transduce signals 




with functional signals transmitted into the APC as well [43, 44]. Further complicating 
immune modulation by B7 family members is the more recent discovery that PD-L1 and 
B7-1 can indeed bind, and that is interaction is inhibitory and signals bidirectionally [45]. 
 
The current study has documented expression of a B7 family costimulatory molecule, 
B7-H3, on FLS and other fibroblasts, which are not typically viewed as professional 
APC. Unlike professional APC, which only express B7-H3 after activation [15], FLS 
expression is constitutive and uninfluenced by immunoregulatory cytokines. This 
constitutive B7-H3 expression is overwhelmingly of the 4Ig isoform and is robust both in 
vivo and in vitro.   
 
The literature on the effects of B7-H3 on T cells has not hitherto provided consensus as to 
its function. B7-H3 was originally described in human systems as a 2Ig costimulatory 
molecule that increased T cell proliferation, enhanced cytotoxicity, and increased IFNγ 
production [15]. However, a subsequent study indicated that the predominant isoform of 
B7-H3 is the 4Ig form [17]. This report did not recapitulate the costimulatory effects 
originally documented. In yet another study, NK lysis of neuroblastoma lines was 
enhanced by blocking antibodies against 4Ig B7-H3 [46].  
 
Studies of B7-H3 in mice, which only contain one isoform, 2Ig [16, 18], do not resolve 
this issue. B7-H3 knockout mice showed increased airway hypersensitivity and earlier 
onset of EAE [20]. Similar results were obtained using B7-H3 blocking antibodies, 




by B7-H3 blockade [19]. In contrast to reports in humans, tumor expression of B7-H3 
enhances cytotoxicity [21, 22]. And when B7-H3 knockout mice are used in allograft 
survival studies, B7-H3 deficient transplants fare better when combined with 
immunosuppression [23]. Thus far, there appears to be no specific and consistent 
association of 2Ig or 4Ig B7-H3 with activating or inhibitory effects. 
 
We found B7-H3 expression was associated with FLS rich areas and was in close 
proximity to T cells in the RA pannus. When the T cell-FLS interaction was explored by 
confocal microscopy, B7-H3 was found at the contact point, but was differentially 
localized from CD54 and LFA-1. This suggested that B7-H3 could be an important 
signaling molecule between FLS and T cells. However, knockdown of B7-H3 in FLS did 
not affect the ability of FLS to present superantigen to T cells or to respond to contact 
with T cells by the secretion of IL-6 and IL-8 (data not shown). Nevertheless, interesting 
B7-H3 dependent effects on cytokine secretion by T cells following co-culture with FLS 
were documented, including the differential effects of B7-H3 on cytokine production by 
resting or cytokine activated T cells. This suggests that the activation state of the T cell 
has significant influence over the outcome of T cell ligation of B7-H3, and also suggests 
that there may be two receptors for B7-H3 (which is a pattern that would be similar to 
other B7 family ligands). Furthermore, cytokine production by TCD3 did not greatly differ 
after co-culture with B7-H3 expressing or knockdown FLS.  
 
A simplistic model to explain our observations would be that resting T cells 




predominantly express an activating receptor for B7-H3. T cells activated through 
stimulation by CD3 and CD28 did not have significant differences in cytokine 
production, suggesting that this type of activated T cells does not express a functionally 
significant level of B7-H3 receptor, or that, perhaps, opposing effects of engagement of 
both positive and negative receptors are offsetting. So far we have not observed an effect 
on FLS, by engagement or interference with B7-H3 signaling, implying that perhaps B7-
H3 signaling is not bidirectional in FLS-T cell interactions as compared to interactions of 
T cells with professional APC. However, an alternative possibility is that other assays 
need to be employed to measure the functional consequences of B7-H3 engagement on 
the B7-H3 expressing cells. 
 
Costimulation in RA 
The strong expression of B7-H3 by FLS of the RA pannus raises interesting issues 
regarding costimulation of T cells in RA. It has been suggested that an unusual subset of 
CD4+CD28null T cells is expanded in RA [47, 48]. These T cells are likely to require 
costimulatory signals distinct from CD80/CD86. There is evidence that constant exposure 
to TNFα (which is abundant in RA) blocks the transcription of CD28 [49]. These 
CD4+CD28null T cells have been shown to be potent producers of cytokines (including 
TNFα and IFNγ) [50], and to also express costimulatory molecules normally associated 
with NK cells [51]. It will be interesting to determine whether this CD4+CD28null T cell 
subset interacts with FLS through the B7-H3 molecule. 
 




Recent trials indicate that the drug Abatacept (CTLA-4-IgG fusion protein) has clinical 
benefit in RA [52]. Unfortunately, as with all current therapy for RA, complete remission 
of disease is unlikely. Nonetheless the clinical data proves that interference with 
costimulatory molecules may be an effective approach for treatment of RA, and it is 
likely that targets other than CD28 will also be studied. The robust, constitutive and 
selective expression of B7-H3 by FLS in vivo and in vitro, and its involvement in FLS/T 
cell interactions implies a unique and significant role for this molecule in the 
pathogenesis of synovitis. Definition of its receptor(s) on the T cell, and further insights 
into their costimulatory or inhibitory signaling functions will be required in order to 
determine whether B7-H3 or its receptor(s) are, like CD28, potential targets for novel 

















Figure 4-1. FLS express the B7 family molecule B7-H3. 
A) FLS were stimulated with IFNγ for 72 hours. FLS were removed from culture wells 
with EDTA and stained with mouse anti-human B7-H3 antibody (solid black line), 
mouse anti-human ICOS-L (dashed black line), or control mouse IgG (solid grey line). B) 
The panel of antibodies was expanded in a separate experiment to include B7-H3 (solid 
black line), PD-L2 (dashed black line), B7-H1 (solid dark grey line), or mouse IgG 




























Figure 4-2. Fibroblasts from various tissue sources express B7-H3. 
RA FLS, OA FLS, lung fibroblasts, and skin fibroblasts were stimulated with TNFα, 
IFNγ, IL-1β, IL-17, IL-4, or IL-10 for 72 hours. Fibroblasts were removed from culture 
wells with EDTA and stained with mouse anti-human B7-H3, CD54, or control antibody. 






















Figure 4-3. Fibroblasts express the 4Ig isoform of B7-H3. 
Numbers shown to the left of each panel represent molecular mass markers (kDA). A) 
Recombinant 4Ig and 2Ig B7-H3 was separated on SDS PAGE and stained with goat 
anti-human B7-H3 antibody. After transfer to Immobilon-P, blots were developed by 
rabbit anti-goat HRP and ECL. B) RA FLS whole cell lysates were precleared, and then 
separated on SDS PAGE, blot transferred, and developed with goat anti-human B7-H3 
antibody or goat IgG. Lysates from the same RA FLS line were run in all lanes. These 
results representative of two experiments. C) Whole cell lysates from RA FLS, OA FLS, 
lung fibroblasts, and skin fibroblasts were run on SDS-PAGE without preclearing, blot 
transferred, and developed with goat anti-human B7-H3 antibody or goat IgG. The film 






























Figure 4-4A&B. B7-H3 expression within the RA synovium 
Sections RA synovial tissue were stained. Sections are representative of these 
experiments and come from RA tissue. A) B7-H3 staining was compared to cadherin-11 
and CD90 staining on frozen sections. To control for dichromatic staining, control 
antibody was developed in blue for B7-H3/Cadherin-11 and red for CD90. Images were 
taken at 20X magnification. B) Paraffin embedded sections of RA synovial tissue were 
dually stained with goat anti-human B7-H3 (red) and mouse anti-human CD20, CD45, or 


























C) Frozen sections were stained dually stained with goat anti-human B7-H3 (red) and 
mouse anti-human CD3 or CD80 (both blue). Images taken at 40X magnification. D) 
CD3 (blue) staining was compared to cadherin-11 (red) staining on frozen sections, with 
goat-IgG control for cadherin-11 (red) (top). In addition, CD3 (red) was compared to 





















Figure 4-5. B7-H3 localization at the T cell/FLS synapse. 
A) FLS were grown on glass coverslips and co-cultured with Tsea, Tck, or Trest for 24 
hours. Coverslips were fixed in 4% paraformaldehyde and stained with goat anti-human 
B7-H3 (green) and CD3 (red). B) Staining of B7-H3 (green) and CD3 (red) after 2 hours 




























Figure 4-6 B7-H3 localization compared to CD54 and LFA-1 localization at the T 
cell/FLS synapse. 
Images are representative of three experiments and digitally zoomed before capture. A) 
FLS were transfected with an expression vector for CD54-eGFP fusion protein (green) 
before plating on glass coverslips and co-culture with Tck. Tck were stained with anti-
LFA-1 (red). This image is the bottom row of Figure 3-4. B) Tck were co-cultured with 
FLS and stained for B7-H3 (green) and CD54 (red). C) B7-H3 (green) dually stained 





















Figure 4-7. B7-H3 specific RNAi knockdown B7-H3 long term cultures. 
FLS were transfected with pooled B7-H3 specific RNAi, pooled control RNAi, or mock 
transfected (with no RNAi) before staining with B7-H3 (black line), CD98 (dashed line), 
or control mouse IgG (gray fill) at 12 days post transfection. Histograms are 



































Figure 4-8 T cell cytokine production after co-culture with B7-H3 RNAi transfected FLS. 
FLS were transfected with pooled B7-H3 RNAi (B7-H3), pooled control RNAi (Control), 
or mock transfected (No RNA) and co-cultured with Trest, Tck or Tcd3/cd28. T cells 
were harvested after 8 days of co-culture and restimulated with PMA and ionomycin. 
Supernatants were measured for cytokines by ELISA. Error bars represent 95% 
confidence intervals. Figures are representative of three experiments. A) TNFα. Using 
two tailed t-Test analysis comparing cytokine production from Trest, cultured with B7-
H3 negative FLS (B7-H3) to B7-H3 positive FLS (Control) and with B7-H3 negative 
FLS (B7-H3) to mock transfected (No RNA), yielded p-values <0.0021 and <2.2x10-5 
respectively. Similarly t-Test analysis for Tck yielded p-values <9.1x10-8 and <5.6x10-7 
respectively. B) IFNγ. p-values for Trest cytokine production are <1.8x10-5 and <0.0013 
respectively, and for Tck are <2.8x10-9  and <1.2x10-7 respectively. C) IL-2. p-values for 
Trest cytokine production are <2.5x10-5 and <0.0005 respectively, and for Tck are 
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5-1. Summary of findings 
FLS presentation of arthritogenic peptides 
Extending the earlier findings of FLS presentation of superantigens to T cells, we focused 
on whether FLS could serve as APCs for peptide specific responses. When FLS were 
used as APCs for immunodominant peptides from the arthritogenic antigens HCgp39 and 
hCII, we found that T cell hybridomas recognized antigenic peptides presented by FLS 
and released IL-2. Demonstrating that true antigen presentation was occurring between 
FLS and T cell was important, because of the various antigen independent signaling 
pathways possible between these cell types. Similar to professional APCs, antigen 
presentation by FLS was dependent on functional MHC II, which was induced by IFNγ.  
The HLA-DR4 alleles of the FLS and the corresponding TCR on T cells had to be 
precisely matched to engender a T cell response, illustrating MHC restriction as well as 




antigens that could be presented to the HCgp39 and hCII specific T cell hybridomas, 
respectively. However, there are as yet unidentified factors present in SF that may inhibit 
or augment FLS antigen presentation in the presence of adequate levels of antigen. Given 
the expression of MHC II by FLS in vivo, coupled with FLS-T cell proximity in pannus 
lesions and chronic exposure to autoantigens, these results suggest that FLS might be an 
important APC in the inflamed synovium.  
 
Further work must be done to support the hypothesis that in vivo FLS antigen 
presentation is of importance in RA. Although, T cell hybridomas are a good measure of 
antigen presentation they are not ideal representations of human RA T cells. 
Recapitulation of our findings using human T cell lines or clones developed against hCII 
or HCgp39 would be strong support for FLS APC function in RA. The exact mechanism 
of antigen presentation used by FLS also remains to be discovered. Is this mechanism 
identical to professional APC such as dendritic cells and macrophages? Do FLS possess 
the intracellular machinery necessary to degrade proteins to their antigenic peptides or 
can they only process and present small peptides?  
 
Along similar lines, do all fibroblasts possess innate APC capabilities and how does this 
relate to our understanding of autoimmune disease? We have shown that some lung 
fibroblast lines can present antigen similar to FLS. Is this APC potential of FLS and other 
fibroblasts only manifested in settings of chronic inflammatory cytokine exposure (i.e. an 
autoimmune setting)? And how does the initiation and continuation of antigen 




autoimmune response (RA)? If all fibroblasts possess innate APC potential, are 
fibroblasts important in extra-articular manifestations of RA, or in diseases in which 
fibrosis of tissue rather than tissue destruction by fibroblasts is the pathologic hallmark? 
To answer these questions, it will be necessary to further dissect out the components of 
antigen presentation in RA by professional APC and FLS. 
Tck interactions with FLS 
 
Earlier imaging analysis in our laboratory of FLS and T cell interactions utilized opposite 
states of T cell activation: resting and superantigen activated. We turned our attention 
towards a distinct type of T cell, the Tck, which is activated not by TCR engagement, but 
instead by a cytokine cocktail composed of mediators relevant to RA. Even more than 
Trest, Tck could potently activated FLS in cocultures and this effector function 
synergized with IL-17. Imaging of Tck/FLS cocultures documented extensive cellular 
interactions, and confocal imaging found colocalization of the ICAM-1 and LFA-1 to the 
Tck/FLS synapse. However, blocking antibodies against LFA-1 or ICAM-1 could not 
significantly inhibit Tck activation of FLS. Significant reduction in Tck activation of FLS 
was, however, observed with TNFα blockade, but soluble TNFα could not be detected in 
coculture supernatants. Effective inhibition of Tck effector function on FLS was obtained 
by blockade of membrane-bound TNF on Tck. These findings suggest that in addition to 
the soluble TNFα produced from synovial macrophages, membrane bound TNFα on Tck 





Given the lack of response to initial T cell targeted therapies and the robust therapeutic 
effects seen after TNFα blockade, it appeared that cytokine networks were key to RA 
treatment. However, recent trials demonstrate that T cell targeted therapies (e.g. CTLA4-
Ig) also improve clinical and radiographic endpoints in RA. In theory, CTLA4-Ig would 
inhibit T cells indirectly by costimulation deprivation or directly inhibit APC. So, in 
addition to cytokine networks, the T cell once again is an attractive target for RA therapy 
and by extension a likely culprit in RA pathology. The Tck provides a novel in vitro 
model to mimic RA T cells. It would be of great interest if RA T cells from patients also 
expressed biologically active, membrane bound TNFα. Along similar lines and given the 
promiscuity of B7 receptor-ligand interactions, would CTLA4-Ig inhibit Tck ability to 
active FLS and would this effect synergize with TNFα blockade? No RA therapy has 
produced complete remission of symptoms in a majority of patients with RA, and this is 
paralleled by our in vitro studies of incomplete inhibition of FLS activation by TNF 
blockade. It is distinctly possible (and rather likely) that other cognate receptor-ligand 
interactions, as yet unidentified, contribute to FLS-T cell signaling. 
 
The Role of B7-H3 on FLS 
 
Extending the identification of further mechanisms of FLS-T cell interactions, we found 
that FLS constitutively express the B7 family member, B7-H3, but not other B7 family 
ligands.  In contrast to observations with immune cells, immunoregulatory cytokines did 
not modulate FLS B7-H3 expression. Western blot analysis confirmed that the 4Ig 




staining of RA synovial sections showed that B7-H3 expression was robust in vivo and 
mirrored the expression of the FLS marker cadherin-11, and the fibroblast marker CD90. 
B7-H3 expression in synovial lesions was distinct from B cells, but did show some 
overlap with macrophage regions. T cell markers in synovial sections were also distinct 
from B7-H3, but were in close proximity to FLS. Confocal fluorescence imaging of 
Tck/FLS cocultures showed B7-H3 localization near the contact point between the two 
cell types. Based upon our data of ICAM-1/LFA-1 colocalization to the contact site 
between FLS and Tck, we compared B7-H3 localization to LFA-1 and ICAM-1. B7-H3 
localized near the contact point of FLS and Tck, but in regions distinct from LFA-1 and 
ICAM-1. When B7-H3 was knocked down in FLS by RNAi and these FLS were used to 
stimulate different types of T cells, it was found that Tck cytokine production was 
inhibited and Trest cytokine production was enhanced relative to controls, indicating that 
putative receptors for B7-H3 are activating in Tck while inhibitory in Trest.  
 
These results raise the question of what role B7-H3 plays in the immune system and, 
given FLS strong constitutive expression of B7-H3, what part it plays in RA pathology. 
The different isoforms of human B7-H3 need to be more fully differentiated in terms of 
effector function and tissue/cellular expression profile. In this regard, do the two isoforms 
signal differently, are they differentially expressed temporally, and what influences 
expression of one over the other? All of these questions also beg the discovery of the 
counter ligand(s) to B7-H3. After this ligand is discovered, its expression profile and 
tissue distribution would be quite informative. Based upon our data and likely similar to 




receptors, one inhibitory and one activating. Would the different isoforms of B7-H3 have 
distinct preference for activating or inhibitory receptors? Do CD28-negative T cells, a 
subset that is expanded in RA, preferentially express ligands for B7-H3?  It is exciting to 
think that similar to CTLA4-Ig, one of these receptors could become a potent therapy in 
autoimmune disease. 
 
Much thought has been given to B7 family members as costimulatory molecules, but they 
also signal into the cells on which they are expressed. On this front much work still needs 
be accomplished to discern what effect (if any) ligation of B7-H3 has upon the cells 
which express it. Similarly, does ligation of different isoforms result in different 
signaling? Thus far we have not seen a functionally different response from FLS that 
have had B7-H3 knocked down by RNAi. 
 
Once these questions have been answered, the results will hopefully provide another 
therapeutic target for RA and possibly other autoimmune diseases. At the least, it will 
further understanding of the immune system’s complexity. 
 
5-2. In closing 
T cell/FLS cross-talk is an important pathologic mechanism in RA. These two cell types 
share potent interactions via antigen dependent and antigen independent mechanisms – 
following some known paradigms of immune system function but also interacting in 
completely novel mechanisms. These interactions may ultimately prove to be effective 




approaches, ranging from ex vivo studies of RA tissues to genetic and immunologic 
interventions in animal models, will further establish the conceptual basis for new 
treatment strategies. 
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